EX-10.510-Q·CIK 1788028·0001213900-26-120161

License Agreement, Dated July 13, 2026, by and Between Mirador Therapeutics, Inc. and Kira Pharmaceuticals

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 08:06 EST

Exhibit 10.5

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

EXECUTION VERSION

CONFIDENTIAL

LICENSE AGREEMENT

BETWEEN

MIRADOR THERAPEUTICS, INC.

AND

KIRA PHARMACEUTICALS

LICENSE AGREEMENT

This License Agreement (this “Agreement”) is entered into as of July [●], 2026 (the “Effective Date”) by and between Mirador Therapeutics, Inc., a corporation organized under the laws of The State of Delaware (“Mirador”), on one hand, and Kira Pharmaceuticals, a corporation registered and existing under the laws of the Cayman Islands (“Kira Cayman” or “Kira”), and, solely with respect to Section 10.22, Kira Pharmaceuticals (Suzhou) Ltd., a corporation organized under the laws of China (“Kira Suzhou”), on the other hand. Mirador and Kira each may be referred to herein individually as a “Party” or collectively as the “Parties.”

RECITALS

** **

WHEREAS, Kira or its Affiliate owns or controls certain Patents and Know-How relating to a Licensed Antibody and Licensed Compound directed to C5a and C5aR, including pursuant to that certain license agreement between Kira and the Trustees of the University of Pennsylvania (“Penn”) effective as of June 9, 2017, as amended by the First Amendment to License Agreement effective as of June 7, 2019, the Second Amendment to License Agreement effective as of February 4, 2021, and the Third Amendment to License Agreement effective as of July 9, 2026 (the “Third Amendment”) (such license agreement with Penn, together with all such amendments, the “Penn License”);

** **

WHEREAS, Mirador is a next-generation precision medicine company focused on diseases of immunology and inflammation; and

** **

WHEREAS, Kira desires to grant to Mirador, and Mirador desires to receive, an exclusive license (or sublicense, as applicable) under the Licensed Technology (as defined below) to Exploit Licensed Products in the Field (all as further defined below), subject to the terms and conditions set forth herein;

** **

NOW, THEREFORE, in consideration of the respective covenants, representations, warranties and agreements set forth herein, the Parties agree as follows:

ARTICLE 1.

DEFINITIONS

For purposes of this Agreement, the following capitalized terms will have the following meanings:

** **

1.1. “AAA” has the meaning set forth in Section 10.14.2(a).

** **

1.2. “Accelerated Milestone Payment” has the meaning set forth in Section 10.4.2.

** **

1.3. “Acquisition Transaction” has the meaning set forth in Section 3.4.2.

** **

1.4. “Actual Effective Royalty Rate” has the meaning set forth in Section 4.4.7.

** **

1.5. “Affiliate” means, as of any point in time and for so long as such relationship continues to exist with respect to any Person, any other Person that controls, is controlled by or is under common control with such Person. A Person will be regarded as in control of another Person if it (a) owns or controls, directly or indirectly, more than fifty percent (50%) of the equity securities of the subject Person entitled to vote in the election of directors (or, in the case of a Person that is not a corporation, for the election of the corresponding managing authority), or (b) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of such Person (whether through ownership of securities or other ownership interests, by contract or otherwise).

** **


2

** **

1.6. “Agreement” has the meaning set forth in the Preamble.

** **

1.7. “Annual Net Sales” means, with respect to a Licensed Product, the aggregate Net Sales of such Licensed Product sold by Mirador, its Affiliates or Sublicensees in the Field in the Territory during a Calendar Year and only during the Royalty Term for such Licensed Product in the applicable country.

** **

1.8. “Applicable Law” means all applicable laws, statutes, rules, regulations and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including any applicable rules, regulations, guidelines, or other requirements of the Regulatory Authorities that may be in effect from time to time.

** **

1.9. “Approval Application” means a BLA, NDA or similar application or submission for a Licensed Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries.

** **

1.10. “Arbitration Notice” has the meaning set forth in Section 10.14.1.

** **

1.11. “Audited Party” has the meaning set forth in Section 4.8.

** **

1.12. “Auditing Party” has the meaning set forth in Section 4.8.

** **

1.13. “Basket Study” means a Clinical Trial designed to evaluate a particular Licensed Product for more than one Indication.

** **

1.14. “BLA” means a Biologics License Application that is submitted to the FDA for marketing approval for a Licensed Product pursuant to 21 C.F.R. § 601.2.

** **

1.15. “Blocking Third Party Intellectual Property” means, with respect to a Licensed Component or Licensed Product, Patents or Know-How owned or controlled by a Third Party (but not then included in Licensed Technology) that Cover (with respect to Patents) or are necessary or reasonably useful to Develop, Manufacture or Commercialize (with respect to Know-How) such Licensed Component or Licensed Product.

** **

1.16. “Blocking Third Party Intellectual Property Costs” means Out-of-Pocket Costs, including upfront payments, purchase price, milestones, royalties, license fees, and other payments paid after the Effective Date by Mirador or its Affiliates to a Third Party that owns or controls Blocking Third Party Intellectual Property (or that, prior to the applicable transaction with Mirador or its Affiliates, owned or controlled Blocking Third Party Intellectual Property) for the grant of a license or to acquire such Blocking Third Party Intellectual Property.

** **

1.17. “Breaching Party” means the Party that the other Party believes is in material breach of this Agreement.

3

** **

1.18. “Business Day” means a Monday, Tuesday, Wednesday, Thursday or Friday that is not a day on which banking institutions in New York, New York are authorized or obligated to close.

** **

1.19. “Calendar Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 or December 31, during the Term, or the applicable part thereof during the first or last calendar quarter of the Term.

** **

1.20. “Calendar Year” means any calendar year ending on December 31, or the applicable part thereof during the first or last year of the Term.

** **

1.21. “CDA” has the meaning set forth in Section 1.31.

** **

1.22. “Change of Control” means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which (i) a Third Party, together with its Affiliates, becomes the beneficial owner of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party or (ii) the beneficial owners of such Party’s outstanding securities immediately prior to the transaction or series of related transactions do not beneficially own more than fifty percent (50%) of the Party’s outstanding securities after the transaction or series of related transactions other than solely as a result of a *bona fide *financing, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business or assets to which the subject matter of this Agreement relates, provided that a transaction described in this clause (c) shall not be deemed a “Change of Control” for purposes of Section 3.4.3 in the event that all or substantially all of the business or assets acquired pursuant to such transaction are the business and assets to which this Agreement relates.

** **

1.23. “Clinical Trial” means a study in humans that is required to be conducted in accordance with GCP and is designed to generate data in support of an Approval Application.

** **

1.24. “Combination Product” means a Licensed Product containing a Licensed Component and one or more other therapeutically or prophylactically active ingredients or delivery devices that is not a Licensed Component, whether combined in a single formulation or package, as applicable, or formulated separately but packaged under a single label approved by a Regulatory Authority and sold together for a single price.

** **

1.25. “Commencement” means, with respect to any Clinical Trial, dosing of the third (3rd) human subject in such Clinical Trial.

** **

1.26. “Commercialize” or “Commercializing” means to (a) market, promote, distribute, offer for sale, sell, have sold, import, export or otherwise commercialize a Licensed Product, (b) conduct activities, other than research, Development and Manufacturing, in preparation for the foregoing activities, including obtaining Price Approval or (c) conduct post-Marketing Approval studies (including Clinical Trials). When used as a noun, “Commercialization” means any activities involved in Commercializing.

4

** **

1.27. “Commercially Reasonable Efforts” means with respect to the efforts to be expended by any Person with respect to any objective, reasonable, diligent or good faith efforts to accomplish such objective. With respect to Mirador’s obligations set forth in Section 2.5, “Commercially Reasonable Efforts” means: (a), with respect to such obligations for the Licensed Antibody and Licensed Antibody Product(s) Covered by a Penn Patent, those efforts and resources that a similarly situated biotechnology or pharmaceutical company would use for its own internally discovered technology of similar commercial potential and similar stage of development, taking into consideration such factors as such similarly situated company would typically take into consideration, including the likely timing of the technology’s entry into the market and any patent or other proprietary position, and such efforts require that Mirador (i) promptly assign responsibility for such obligations to specific employee(s) who are accountable for progress and monitor such progress on an ongoing basis, (ii) set annual objectives for carrying out such obligations, and (iii) allocate resources designed to advance progress with respect to such objectives; and (b), with respect to such obligations for any Licensed Component or Licensed Product that is not covered by a Penn Patent, that level, caliber and quality of efforts and resources reasonably and normally used by biopharmaceutical companies of similar size to Mirador as to a potential or actual product with similar commercial potential and at a similar stage of product life, taking into account, without limitation, with respect to each applicable Licensed Component or Licensed Product, (i) issues of safety, efficacy and product profile, (ii) likelihood of receiving Marketing Approval and Price Approval for the applicable Licensed Product, existing or projected pricing, sales, and reimbursement, and the projected profitability of the applicable Licensed Product, (iii) regulatory structure involved, (iv) actual or anticipated Regulatory Authority-approved labeling, (v) the expected and actual competitiveness of alternative products in the marketplace, the competitive environment for the applicable Licensed Product in the Indications, the availability and duration of regulatory or other exclusivity, cross-border impacts, the then-current and reasonably anticipated regulatory environment and regulatory status of the applicable Licensed Product, the likelihood of and timing for obtaining all relevant approvals for Commercialization, (vi) proprietary position and other intellectual property rights and development position of other Third Party products relative to the applicable Licensed Product, (vii) the product’s potential relative to other products or programs in Mirador’s portfolio or which Mirador may seek to acquire or develop, and (viii) other relevant scientific, technical and business factors deemed relevant by Mirador.

** **

1.28. “Competitive Infringement” has the meaning set forth in Section 5.4.1.

** **

1.29. “Competitive Product” means, with respect to a particular Licensed Product in a particular country, a product on the market in such country commercialized by any Third Party that is not a Sublicensee and that did not purchase such product in a chain of distribution that included any of Mirador or its Affiliates or Sublicensees, that (a) is approved by the applicable Regulatory Authority, under any then-existing laws and regulations in the applicable country pertaining to approval of generic or biosimilar biologic products, as a “generic” or “biosimilar” (or foreign equivalent) version of such Licensed Product, which approval relies on the Approval Application for such Licensed Product, or (b) is otherwise recognized by the applicable Regulatory Authority as a biosimilar or interchangeable product (or foreign equivalent) to such Licensed Product.

** **

1.30. “Compliance” means, with respect to a Party, the adherence by such Party and its Affiliates to Applicable Law and such Party’s Party Specific Regulations, in each case with respect to the activities to be conducted under this Agreement.

** **

1.31. “Confidential Information” means, with respect to each Party, all Know-How or other information, including proprietary information (whether or not patentable) regarding or embodying such Party’s technology, agents, products, business information or objectives, that is communicated in any way or form by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients, pursuant to this Agreement or that certain Confidentiality Disclosure Agreement between Mirador and Kira dated May 17, 2026 (the “CDA”), whether or not such Know-How or other information is identified as confidential at the time of disclosure. The terms of this Agreement will be considered Confidential Information of both Parties, with both Parties deemed to be the Receiving Party of such Confidential Information. All information and data regarding Licensed Components or Licensed Products will be deemed to be Mirador’s Confidential Information, and the exceptions set forth in clauses (a), (d) and (e) below will not apply to such information and data. Notwithstanding any provision of this Section 1.31 to the contrary, Confidential Information does not include any Know-How or information that: (a) was already known by the Receiving Party (other than under an obligation of confidentiality) at the time of disclosure by or on behalf of the Disclosing Party; (b) was generally available to the public or part of the public domain at the time of its disclosure to the Receiving Party; (c) became generally available to the public or part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement; (d) is disclosed to the Receiving Party (other than under an obligation of confidentiality) by a Third Party who has no obligation to the Disclosing Party not to disclose such information to the Receiving Party; or (e) is independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information belonging to the Disclosing Party. Confidential Information disclosed to the Receiving Party hereunder will not be deemed to fall within the foregoing exceptions merely because broader or related information falls within such exceptions, nor will combinations of elements or principles be considered to fall within the foregoing exceptions merely because individual elements of such combinations fall within such exceptions.

5

** **

1.32. “Control” or “Controlled” means with respect to a Party and to any Know-How, Patent or Materials, possession on the Effective Date or at any time during the Term of the ability by such Party or its Affiliate (whether by sole or joint ownership, license or otherwise), other than pursuant to this Agreement, to grant, without violating the terms of any agreement with a Third Party or incurring an additional financial obligation with respect to the provision or grant of such rights to the other Party (excluding any existing financial obligation pursuant to a Kira In-License Agreement) unless such other Party agrees in writing in advance to make such payments arising from such grant of a license, access or other right, a license, access or other right in, to or under such Know-How, Patent or Materials. Notwithstanding anything in this Agreement to the contrary, a Party and its Affiliates will be deemed to not Control any Patents, Materials or Know-How that are owned or controlled by a Third Party described in the definition of “Change of Control” or by such Third Party’s Affiliates (other than any such Affiliate that was an Affiliate of such Party prior to the Change of Control), (a) prior to the closing of such Change of Control, except to the extent that any such Patents, Materials or Know-How (i) were discovered, developed, invented or created by such Third Party or its Affiliates prior to such Change of Control using or incorporating such Party’s or its pre-existing Affiliate’s Know-How, Materials or Patents or (ii) are used or practiced by or on behalf of such Party or any of its Affiliates in the performance of activities under this Agreement, or (b) after the closing of such Change of Control to the extent that such Patents, Materials or Know-How (i) are discovered, developed, invented or created by such Third Party or its Affiliates (other than such Party or its pre-existing Affiliates) after the closing of such Change of Control without using or incorporating such Party’s or its pre-existing Affiliates’ Know-How, Materials or Patents or any Confidential Information of either Party, (ii) are not discovered, developed, invented or created by personnel who were employees or consultants of such Party or its pre-existing Affiliates or have otherwise been involved in the research, Development, Manufacture or Commercialization of any Licensed Component or Licensed Product and (iii) are not used or practiced by or on behalf of such Party or any of its Affiliates in the performance of activities under this Agreement.

** **

1.33. “Cover” or “Covers” means, as to a compound, product or other technology and Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, keeping, selling, offering for sale or importation of such compound, product or other technology would infringe such Patent in the relevant country where such activity occurs or, as to a pending claim included in such Patent, the making, using, keeping, selling, offering for sale or importation of such compound, product or other technology would infringe such Patent in the relevant country where such activity occurs if such pending claim were to issue in an issued patent without modification.

** **

1.34. “Development” means, with respect to a Licensed Component or Licensed Product, all pre-clinical, clinical and non-clinical research and development activities conducted for such Licensed Component or Licensed Product, including discovery, design, optimization, delivery and advancement of Licensed Components and Licensed Products, toxicology, pharmacology test method development and stability testing, process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, Clinical Trials (other than post-Marketing Approval Clinical Trials), regulatory affairs, pharmacovigilance, other activities of obtaining data or information for the purpose of obtaining authorization to conduct Clinical Trials, Clinical Trial regulatory activities, and other activities of seeking, obtaining and maintaining Marketing Approval. When used as a verb, “Develop,” “Developed” or “Developing” means to engage in Development.

6

** **

1.35. “Directed To” means, with respect to an antibody or compound and a target, that such antibody or compound (a) binds specifically to such target and (b) is designed, optimized, or being developed to modulate, alter, or otherwise exert a biological, prophylactic, or therapeutic effect as a result of such binding.

** **

1.36. “Disclosing Party” has the meaning set forth in Section 9.1.

** **

1.37. “Dispute” has the meaning set forth in Section 10.14.

** **

1.38. “Distracting Product” has the meaning set forth in Section 3.4.2.

** **

1.39. “Divest” means, with respect to a Distracting Product, the sale, exclusive license or other transfer by Kira and its Affiliates of all of their development and commercialization rights with respect to such Distracting Product to a Third Party without the retention or reservation of any development or commercialization obligation, interest or participation rights (other than (a) any right required to be retained or granted back solely for the benefit of a Third Party from which Kira or its Affiliates in-licensed or otherwise acquired such rights, (b) an economic interest or (c) the right to enforce the terms contained in the relevant agreement effectuating such transaction).

** **

1.40. “Effective Date” has the meaning set forth in the Preamble.

** **

1.41. “Effective Royalty Rate” has the meaning set forth in Section 4.4.7.

** **

1.42. “EMA” means the European Medicines Agency and any successor entity thereto.

** **

1.43. “End of Effective Royalty Accrual” has the meaning set forth in Section 4.4.7.

** **

1.44. “EU” means the economic, scientific and political organization of member states of the European Union as it may be constituted from time to time, which as of the Effective Date consists of Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and that certain portion of Cyprus included in such organization.

** **


7

** **

1.45. “Europe” means (a) the EU, (b) the United Kingdom of Great Britain and Northern Ireland, (c) any member country of the European Economic Area that is not otherwise a member of the EU, and (d) any country not otherwise included in clauses (a), (b) or (c) that participates in the unified filing system under the auspices of the EMA.

** **

1.46. “European Commission” means the European Commission or any successor entity that is responsible for granting marketing approvals authorizing the sale of pharmaceuticals in Europe.

** **

1.47. “Executive Officers” means the chief executive officer of Kira and the chief executive officer of Mirador, or any other executive vice president designated by a Party in writing who has the authority to resolve the applicable matter referred to the Executive Officers in accordance with this Agreement.

** **

1.48. “Exploit” means, with respect to a Licensed Component or Licensed Product, to Develop, Manufacture, have Manufactured, use, Commercialize and otherwise exploit such Licensed Component or Licensed Product. “Exploiting” and “Exploitation” shall be construed accordingly.

** **

1.49. “FDA” means the United States Food and Drug Administration and any successor entity thereto.

** **

1.50. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder.

** **

1.51. “Field” means all uses and Indications.

** **

1.52. “First Commercial Sale” means with respect to a Licensed Product, the first sale of such Licensed Product by Mirador, its Affiliate or its Sublicensee to a Third Party resulting in Net Sales in a particular country after any required Marketing Approval and Price Approval (if required to sell such product in the applicable jurisdiction) for the Licensed Product have been obtained in such country; provided that the following will not constitute a First Commercial Sale: (a) any sale of a Licensed Product to a Mirador Affiliate or Sublicensee; (b) any sale of a Licensed Product for use in Clinical Trials, pre-clinical studies or other research or Development activities; (c) the disposal or transfer of a Licensed Product for a bona fide charitable purpose; or (d) compassionate use and “named patient sales.”

** **

1.53. “Force Majeure” means a condition, the occurrence and continuation of which is beyond the reasonable control of a Party, including an act of God, governmental acts or restrictions, war, civil commotion, labor strike or lock-out, epidemic or pandemic, flood, failure or default of public utilities or common carriers, and destruction of production facilities or materials by fire, earthquake, storm or like catastrophe.

** **

1.54. “FTE” means a qualified full-time person, or more than one person working the equivalent of a full-time person, where “full-time” is based upon a total of one thousand eight hundred eighty (1,880) working hours per Calendar Year carried out by one or more employees of a Party. Overtime, and work on weekends, holidays, and the like will not be counted with any multiplier (e.g. time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution.

** **

1.55. “FTE Costs” means the total cost incurred by a Party for the time of FTEs who perform a specified activity under this Agreement.

8

** **

1.56. “GAAP” means United States generally accepted accounting principles, consistently applied.

** **

1.57. “GCP” means good clinical practices, which are the then-current standards for Clinical Trials for pharmaceuticals, as set forth in the FD&C Act or other Applicable Law, and such standards of good clinical practice as are required by the Regulatory Authorities of Europe and other organizations and governmental authorities in countries for which the applicable Licensed Component or Licensed Product is intended to be Developed, to the extent such standards are not less stringent than United States standards.

** **

1.58. “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, or comparable regulatory standards in jurisdictions outside of the United States, to the extent such standards are not less stringent than United States standards.

** **

1.59. “GMP” means the then-current Good Manufacturing Practices as specified in the United States Code of Federal Regulations, ICH Guideline Q7A, or equivalent laws, rules or regulations of an applicable Regulatory Authority at the time of manufacture, to the extent such standards are not less stringent than United States standards.

** **

1.60. “Government Official” means (a) any elected or appointed government official (e.g., a member of a ministry of health), (b) any employee or person acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental function, (c) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office, and (d) any employee or person acting for or on behalf of a public international organization (e.g., the United Nations). For clarity, healthcare professionals or healthcare providers employed by government-owned hospitals will be considered Government Officials.

** **

1.61. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision.

** **

1.62. “ICDR” has the meaning set forth in Section 10.14.2(a).

** **

1.63. “IND” means any Investigational New Drug application filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations or a similar application or submission for a Licensed Product filed with a Regulatory Authority in a country or group of countries.

** **

1.64. “Indemnified Party” has the meaning set forth in Section 7.1.4.

** **

1.65. “Indemnifying Party” has the meaning set forth in Section 7.1.4.

** **

1.66. “Indication” means a separate and distinct disease or medical condition in humans which a Licensed Product is intended to treat, prevent or diagnose, where treatment, prevention or diagnosis of such disease or medical condition by a Licensed Product requires receipt of a separate Regulatory Approval, or for which a Licensed Product has received Regulatory Approval. For clarity, any Indication for a Licensed Antibody Product containing a bi-specific or multi-specific antibody comprising a Licensed Antibody would be deemed a second or third Indication and only trigger the milestones thereunder.

** **

1.67. “Insolvency Event” has the meaning set forth in Section 8.2.4.

9

** **

1.68. “Intercompany License Agreement” has the meaning set forth in Section 6.3.11.

** **

1.69. “Kira” has the meaning set forth in the Preamble.

** **

1.70. “Kira Agreement Know-How” has the meaning set forth in Section 5.1.1.

** **

1.71. “Kira Agreement Patents” has the meaning set forth in Section 5.1.1.

** **

1.72. “Kira Agreement Technology” has the meaning set forth in Section 5.1.1.

** **

1.73. “Kira Breach Event” has the meaning set forth in Section 8.2.2(a).

** **

1.74. “Kira Cayman” has the meaning set forth in the Preamble.

** **

1.75. “Kira Indemnified Party” has the meaning set forth in Section 7.1.1.

** **

1.76. “Kira In-License Agreements” has the meaning set forth in Section 4.5.

** **

1.77. “Kira Suzhou” has the meaning set forth in the Preamble.

** **

1.78. “Know-How” means data, results, protocols, chemical structures, chemical sequences, materials, inventions, know-how, formulas, trade secrets, techniques, methods, processes, procedures and developments, and other scientific, technical or manufacturing information, whether or not patentable.

** **

1.79. “Liability” has the meaning set forth in Section 7.1.1.

** **

1.80. “License” has the meaning set forth in Section 3.1.1.

** **

1.81. “Licensed Antibody” means the monoclonal antibody designated internally by Kira as KP301, targeting C5a, with the amino acid sequence set forth on Schedule 1.81, and any binding fragments, modifications, variants, derivatives, or optimizations thereto.

** **

1.82. “Licensed Antibody Product” means any pharmaceutical product containing any Licensed Antibody as a pharmaceutically active ingredient, whether alone or in combination with one or more other pharmaceutically active ingredients, delivery devices, and all formulations, dosage forms and routes of administration, for Exploitation in the Field in the Territory. All Licensed Antibody Products comprising the same Licensed Antibody will be considered the same Licensed Antibody Product under this Agreement.

** **

1.83. “Licensed Component” means any Licensed Antibody or Licensed Compound.

** **

1.84. “Licensed Compound” means (a) the small molecule designated internally by Kira as KP402, targeting C5aR, with the chemical structure set forth in Schedule 1.84, and all modifications, variants, derivatives, improvements, backups or optimizations thereto, including any active metabolite, salt, ester, hydrate, solvate, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, tautomer, or optically active form of any of the foregoing, and (b) any other compound that is covered by any claim of any Patent controlled by Kira that also covers any molecule of clause (a).

10

** **

1.85. “Licensed Compound Product” means any pharmaceutical product containing a Licensed Compound as a pharmaceutically active ingredient, whether alone or in combination with one or more other pharmaceutically active ingredients, delivery devices, and all formulations, dosage forms and routes of administration, for Exploitation in the Field in the Territory. All Licensed Compound Products comprising the same Licensed Compound will be considered the same Licensed Compound Product under this Agreement.

** **

1.86. “Licensed Know-How” means any Know-How Controlled by Kira or its Affiliates on the Effective Date or during the Term that is necessary or reasonably useful to Develop, Manufacture, Commercialize or otherwise Exploit Licensed Components or Licensed Products in the Field in the Territory.

** **

1.87. “Licensed Patents” means any Patents, including Kira Agreement Patents, Controlled by Kira or its Affiliates on the Effective Date or during the Term that (a) Cover any Licensed Know-How or (b) are otherwise necessary or reasonably useful to Develop, Manufacture, Commercialize or otherwise Exploit the Licensed Components or Licensed Products in the Field in the Territory, including all Patents set forth on Schedule 1.87.

** **

1.88. “Licensed Product” means any Licensed Antibody Product or Licensed Compound Product.

** **

1.89. “Licensed Technology” means the Licensed Patents and Licensed Know-How.

** **

1.90. “Major European Market” means each of the following countries: France, Germany, Italy and the United Kingdom.

** **

1.91. “Manufacture” or “Manufactured” or “Manufacturing” means activities directed to making, having made, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality control testing and quality assurance release, shipping or storage of a Licensed Component or Licensed Product.

** **

1.92. “Marketing Approval” means, with respect to a Licensed Product in a particular jurisdiction, all approvals (including regular or accelerated approval of a BLA or NDA), licenses, registrations or authorizations necessary for the Commercialization of such Licensed Product in such jurisdiction, including, with respect to the United States, approval of an Approval Application for such Licensed Product by the FDA and with respect to Europe, approval of an Approval Application for such Licensed Product by the European Commission or the applicable Regulatory Authority in any particular country in Europe.

** **

1.93. “Materials” means chemical compounds, biological materials, including Clinical Trial samples, cell lines, lipids, assays, viruses and vectors, raw materials, kits, and ingredients for manufacturing or testing Licensed Components or Licensed Products, and other materials to the extent in the possession or Control of Kira and its Affiliates. “Materials” excludes Physical Materials.

** **

1.94. “Mirador” has the meaning set forth in the Preamble.

** **

1.95. “Mirador Agreement Know-How” has the meaning set forth in Section 5.1.2.

** **

1.96. “Mirador Agreement Patents” has the meaning set forth in Section 5.1.2.

11

** **

1.97. “Mirador Agreement Technology” has the meaning set forth in Section 5.1.2.

** **

1.98. “Mirador Indemnified Party” has the meaning set forth in Section 7.1.2.

** **

1.99. “NDA” means a new drug application that is submitted to the FDA for marketing approval for a Licensed Product, pursuant to 21 C.F.R. § 314.3.

** **

1.100. “Net Sales” means the gross consideration invoiced or received by Mirador or any of its Affiliates or Sublicensees for Sales of Licensed Product (including any cash amounts plus the fair market value of any other forms of consideration), less the following deductions (to the extent included in and not already deducted from the gross amounts invoiced or otherwise charged) to the extent reasonable and customary and solely related to the sale of such Licensed Product:

(a) trade discounts, including trade, cash and quantity discounts or rebates, credits or refunds;

(b) allowances or credits actually granted upon claims, returns or rejections of products, including recalls, regardless of the party requesting such recall;

(c) charges included in the gross sales price for freight, insurance, transportation, postage, handling and any other charges relating to the sale, transportation, delivery or return of such Licensed Product;

(d) customs duties, sales, excise and use taxes and any other governmental charges (including value added tax) actually paid in connection with the transportation, distribution, use or sale of such Licensed Product (but excluding what is commonly known as income taxes);

(e) rebates and chargebacks or retroactive price reductions made to federal, state or local governments (or their agencies), or any Third Party payor, administrator or contractor, including managed health organizations;

(f) payments required by law to be made under Medicaid, Medicare or other government special medical assistance programs (including, but not limited to, payments made under the new “Medicare Part D Coverage Gap Discount Program” and the “Annual Fee on Branded Pharmaceutical Manufacturers”); and

(g) uncollected amounts due to non-payment actually written off in accordance with GAAP relating to Sales of Licensed Products during the applicable calculation period, net of subsequent recoveries, provided that such amounts shall not be in excess of five percent (5%) of the gross consideration received.

Even if there is overlap between any of the deductions described above, each individual item shall only be deducted once in the overall Net Sales calculation. Each of the above deductions to Net Sales shall be calculated in accordance with GAAP.

Notwithstanding the foregoing, Net Sales shall not include, and shall be deemed zero with respect to: (i) the distribution of promotional samples of Licensed Product provided free of charge, and, (ii) Licensed Products provided for Clinical Trials, Development, or evaluation purposes, provided that such Licensed Product does not exceed twenty percent (20%) of Net Sales of such Licensed Product in any given year after the First Commercial Sale of such Licensed Product.

12

Net Sales of any Combination Product shall be determined on a country-by-country basis as follows: the Net Sales of the Combination Product (prior to application of the following adjustment) shall be multiplied by the fraction A/(A+B), where A is the net selling price in such country of a Licensed Product without the additional product/device/component in the Combination Product, and B is the net selling price in such country of such product/device/component in the combination if sold separately in the same metric or form as contained in the Combination Product. All net selling prices of the elements of such Combination Product shall be calculated as the average net selling price of the said elements during the applicable accounting period for which the Net Sales are being calculated.

Notwithstanding the foregoing, in the case of a Licensed Product that contains a Licensed Antibody that is a multi-specific antibody that includes one or more antibodies for which Mirador has paid or would be obligated to pay a Third Party Net Sales-based payments for such Licensed Product, the Net Sales apportioned under this Agreement for such Licensed Antibody contained in such Licensed Product will be divided by the total number of therapeutic targets to which the Licensed Product binds (e.g., 1/2 of the Net Sales for a bi-specific Licensed Product, 1/3 of the Net Sales for a tri-specific Licensed Product, etc.). Notwithstanding the foregoing, in the event that such reduction is based on non-recurring payments made by Mirador (i.e., not for Net Sales of the combination Licensed Antibody), the reduction will be based on the actual amounts paid by Mirador to such Third Party for such antibody.

** **

1.101. “Non-Breaching Party” means the Party that believes the Breaching Party is in material breach of this Agreement.

** **

1.102. “Out-of-Pocket Costs” means, with respect to a Party, costs and expenses paid by such Party or its Affiliates to Third Parties (or payable to Third Parties and accrued in accordance with GAAP), other than employees of such Party or its Affiliates.

** **

1.103. “Party” or “Parties” has the meaning set forth in the Preamble.

** **

1.104. “Party Specific Regulations” means all non-monetary judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party’s activities contemplated by this Agreement.

** **

1.105. “Patents” means the rights and interests in and to issued patents and pending patent applications in any country, jurisdiction or region (including inventor’s certificates and utility models), including all provisionals, non-provisionals, substitutions, continuations, continuations-in-part, divisionals, renewals and all patents granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations and patents of addition thereof, including patent term extensions and supplementary protection certificates, international patent applications filed under the Patent Cooperation Treaty (PCT) and any foreign equivalents to any of the foregoing.

** **

1.106. “Penn” has the meaning set forth in the Recitals.

** **

1.107. “Penn Indemnitees” has the meaning set forth in Section 7.1.3.

** **

1.108. “Penn License” has the meaning set forth in the Recitals.

** **

1.109. “Penn Patent” means the Licensed Patents licensed from Penn to Kira under the Penn License, including those Patents set forth on Schedule 1.109.

13

** **

1.110. “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.

** **

1.111. “Phase 1 Clinical Trial” means any Clinical Trial as described in 21 C.F.R. §312.21(a), or, with respect to a jurisdiction other than the United States, an equivalent Clinical Trial.

** **

1.112. “Phase 2 Clinical Trial” means a Clinical Trial as described in 21 C.F.R. §312.21(b), or, with respect to a jurisdiction other than the United States, an equivalent Clinical Trial.

** **

1.113. “Phase 3 Clinical Trial” means any Clinical Trial as described in 21 C.F.R. §312.21(c), or, with respect to a jurisdiction other than the United States, an equivalent Clinical Trial.

** **

1.114. “Physical Materials” means physical samples of Licensed Antibody(ies), cell lines used to manufacture Licensed Antibody(ies), Licensed Compound(s) or Licensed Product(s), and any drug substance, drug product or other tangible materials relating to the foregoing to the extent in the possession or Control of Kira or its Affiliates, including those materials listed on Schedule 1.114.

** **

1.115. “Price Approval” means, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination.

** **

1.116. “Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or in equity or before any Governmental Authority.

** **

1.117. “Prosecution and Maintenance” or “Prosecute and Maintain” means, with regard to a Patent, the preparing, filing, prosecuting and maintenance of such Patent, as well as handling re-examinations and reissues with respect to such Patent, together with the conduct of interferences, derivation proceedings, the defense of oppositions, post-grant patent proceedings (such as inter partes review and post grant review) and other similar proceedings with respect to the particular Patent. For clarification, “Prosecution and Maintenance” or “Prosecute and Maintain” will not include any other enforcement actions taken with respect to a Patent. “Prosecuting and Maintaining” shall be construed accordingly.

** **

1.118. “Receiving Party” has the meaning set forth in Section 9.1.

** **

1.119. “Regulatory Approval” means the technical, medical and scientific licenses, registrations, authorizations, clearances, accreditations and approvals (including approvals of Approval Applications, supplements and amendments, pre- and post- approvals, and labeling approvals) of any Regulatory Authority, necessary for the research, development, clinical testing, commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of a pharmaceutical product in a regulatory jurisdiction, including Marketing Approval and Price Approval.

** **

1.120. “Regulatory Authority” means, with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the granting of Regulatory Approvals or Price Approvals for pharmaceutical products in such country or countries.

14

** **

1.121. “Regulatory Filings” means, collectively: (a) all (i) INDs or other filings needed to initiate clinical testing of any pharmaceutical product, (ii) Approval Applications, establishment license applications and drug master files, (iii) applications for designation as an “Orphan Product(s)” under the Orphan Drug Act, or (iv) applications for “Fast Track” status, “Breakthrough Therapy” status or “Regenerative Medicine Advanced Therapy Designation” under Section 506 of the FD&C Act (21 U.S.C. § 356) or for a Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the FD&C Act (21 U.S.C. § 355(b)(4)(B)) and all other similar filings (including counterparts of any of the foregoing in any country or region in the Territory); (b) any applications for Regulatory Approval or Price Approval and other applications, filings, dossiers or similar documents submitted to a Regulatory Authority in any country for the purpose of obtaining Regulatory Approval or Price Approval from that Regulatory Authority; (c) any supplements and amendments to any of the foregoing; and (d) any correspondence with any Regulatory Authority relating to any of the foregoing.

** **

1.122. “Royalty Term” means, with respect to a Licensed Product in a country, the period commencing on the First Commercial Sale of such Licensed Product in such country and ending upon the latest of: (a) the expiration of the last-to-expire Valid Claim of a Licensed Patent that Covers the make, use, or sale of such Licensed Product in such country; (b) twelve (12) years after the First Commercial Sale of such Licensed Product in such country; or (c) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such Licensed Product.

** **

1.123. “Sale” means any transaction for which consideration is received or expected by Mirador, its Affiliates or Sublicensees for sale, use, lease, transfer or other disposition of a Licensed Product to or for the benefit of a Third Party. For clarity, sale, use, lease, transfer or other disposition of a Licensed Product by Mirador or any of its Affiliates or Sublicensees to another of these entities for resale by such entity to a Third Party shall not be deemed a Sale.

** **

1.124. “SDR Report” has the meaning set forth in Section 3.1.2(d).

** **

1.125. “Setoff Amount” has the meaning set forth in Section 8.3.

** **

1.126. “Sublicense” means, when used as a verb, directly or indirectly, to sublicense, grant any other right with respect to, or agree not to assert, the rights granted to Mirador hereunder. When used as a noun, “Sublicense” means any agreement to Sublicense.

** **

1.127. “Sublicense Documents” means any and all agreements, amendments or written understandings entered into with a Sublicensee (including any of its Affiliates) that are directly or indirectly related to a Sublicense, Licensed Technology, Licensed Components or Licensed Product. For clarity, a development agreement or distribution agreement for a Licensed Product is a Sublicense Document.

** **

1.128. “Sublicensee” means a Third Party to whom Mirador (or a Sublicensee or Affiliate) sublicenses any of the rights granted to Mirador hereunder during the Term.

** **

1.129. “Term” has the meaning set forth in Section 8.1.

** **

1.130. “Territory” means worldwide.

15

** **

1.131. “Third Party” means any Person other than Mirador, Kira or their respective Affiliates.

** **

1.132. “Third-Party Infringement Claim” has the meaning set forth in Section 5.3.

** **

1.133. “Total Milestone Payments” has the meaning set forth in Section 4.4.7.

** **

1.134. “Unadjusted Effective Royalty Rate” has the meaning set forth in Section 4.4.7.

** **

1.135. “United States” or “U.S.**” means the United States of America and all of its districts, territories and possessions.

** **

1.136. “Valid Claim” means a claim of (a) an issued and unexpired United States or foreign Patent in the Licensed Patents, which claim has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no further appeal can be taken or has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer, or (b) a pending United States or foreign patent application that is included in the Licensed Patents, which was filed and is being prosecuted in good faith, and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application.

ARTICLE 2.

DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION

** **

2.1. Development.

** **

2.1.1. Generally. Mirador will have sole and exclusive control over, and decision-making authority with respect to, all matters relating to the Development of Licensed Components and Licensed Products.

** **

2.1.2. Development Plan. No later than November 15th of each year during the Term, Mirador and its Sublicensees shall submit a development plan (or updated development plan), which shall set forth the activities (or include amendments and revisions to any long term Development activities) and the associated timelines of when such activities shall be conducted (including in detail the activities that shall be conducted in the Calendar Year following submission of such development plan to Kira). Notwithstanding the foregoing, such updated development plan for a given Licensed Product shall not be due after the First Commercial Sale of such Licensed Product, and no development plan shall be due after the First Commercial Sale of Products covered by all patent families of the Penn Patents.

** **

2.1.3. Reporting. For so long as Mirador is conducting Development activities with respect to the Licensed Components or Licensed Products, on a semiannual basis but in no event later than May 15th and November 15th of each Calendar Year, Mirador will provide Kira with a written report regarding the status of Mirador’s Development of Licensed Components and Licensed Products for such Calendar Year, which such report will include sufficient detail to allow Kira to comply with the obligations under Section 3.4.2 of the Penn License as applicable to Mirador’s Development activities.

16

** **

2.2. Regulatory Matters.

** **

2.2.1. Responsibilities. Mirador will have the sole and exclusive authority over, and decision-making authority with respect to, all regulatory matters related to the Licensed Components and Licensed Products in the Field in the Territory, including the (a) preparation and filing of Regulatory Filings, each in its own name (or the name of its designee(s)), for all Licensed Components and Licensed Products in the Field in the Territory, and (b) communication with Regulatory Authorities with respect to the Licensed Components and Licensed Products in the Field in the Territory, both prior to and following Marketing Approval and Price Approval, including all communications and decisions with respect to (i) labeling of Licensed Products, and (ii) the negotiation of Price Approvals. Without limiting the foregoing, during the Term, neither Kira nor its Affiliates will prepare or file any Regulatory Filings with any Regulatory Authority with respect to any Licensed Component or Licensed Product in the Field in the Territory.

** **

2.2.2. Ownership. Ownership of all right, title and interest in and to all Regulatory Filings, Regulatory Approvals and Price Approvals directed to any Licensed Component or Licensed Product in the Field in each country of the Territory will be held by and in the name of Mirador, its Affiliate, designee or Sublicensee.

** **

2.2.3. Cooperation. Kira will, and will cause its Affiliates to, reasonably cooperate with Mirador with respect to all regulatory matters relating to any Licensed Component or Licensed Product. Without limiting the foregoing, as reasonably requested by Mirador, Kira will assist Mirador in preparing Regulatory Filings for Licensed Products and make Licensed Know-How Controlled by Kira or its Affiliates available to Mirador to the extent necessary or reasonably useful in connection with such Regulatory Filings to the extent such Licensed Know-How has not previously been delivered or otherwise made available to Mirador by Kira or its Affiliates (including pursuant to this Section 2.2 or Section 3.2). Upon Mirador’s reasonable request, Kira will support the Development of Licensed Components and Licensed Products by providing Regulatory Authorities with access to, and the right to audit, any Licensed Know-How and associated documents that are in Kira’s Control and are relied on by Mirador in its Regulatory Filings for Licensed Components and Licensed Products to the extent such Licensed Know-How is not in the possession or Control of Mirador or such Regulatory Authority expressly requests to audit Kira. Kira will not make any submission, response, or other communication to any Regulatory Authority with respect to the Licensed Components and Licensed Products in the Field in the Territory without first obtaining Mirador’s prior written consent; provided that the foregoing shall not be deemed to require Kira to violate a request by a Regulatory Authority if first obtaining such consent is not practicable. With respect to the activities contemplated in this Section 2.2.3, (a) Mirador will reimburse Kira for all Out-of-Pocket Costs paid by Kira to a Third Party and (b) Mirador will be responsible for all FTE Costs incurred by Kira. Mirador shall pay Kira for such Out-of-Pocket Costs and FTE Costs within thirty (30) days following receipt of invoice.

** **

2.3. Manufacturing. Mirador will have sole and exclusive control over, and decision-making authority with respect to, all matters related to the Manufacture and supply of Licensed Components and Licensed Products for Exploitation in the Field in the Territory.

** **

2.4. Commercialization.

** **

2.4.1. General. Mirador will have sole and exclusive control over, and decision-making authority with respect to, all matters relating to the Commercialization of Licensed Products in the Field in the Territory.

** **

2.4.2. Branding. Mirador will have sole and exclusive control over, and decision-making authority with respect to, all matters relating to the selection of all trademarks used in connection with the Commercialization of any Licensed Product in the Field in the Territory and Mirador or its designee(s) shall own all of such trademarks.

** **


17

** **

2.5. Mirador Diligence. Mirador (acting directly or through one or more Affiliates or Sublicensees) will use Commercially Reasonable Efforts to Develop, seek Marketing Approval for and, following receipt of Marketing Approval, achieve First Commercial Sale for at least one Licensed Product for at least one Indication in the Field in the U.S.

ARTICLE 3.

LICENSE GRANTS; Exclusivity

** **

3.1. License Grant to Mirador.

** **

**3.1.1. **License. Subject to the terms and conditions of this Agreement, Kira and its Affiliates hereby grant to Mirador and its Affiliates an exclusive (even as to Kira), royalty-bearing license, including the right to grant Sublicenses through multiple tiers in accordance with Section 3.1.2, under Kira’s and its Affiliates’ interest in the Licensed Technology to Exploit the Licensed Components and Licensed Products in the Field in the Territory (the “License”). Notwithstanding the foregoing, Mirador shall only have a non-exclusive, sublicensable (only to the extent the sublicense is in connection with the sublicense of Penn Patents) license to use the Penn Mouse Models (as defined in the Penn License) for internal research purposes only.

** **

3.1.2. Sublicensing.

(a) Mirador and its Affiliates may grant Sublicenses of any rights granted to Mirador and its Affiliates by Kira under this Agreement through multiple tiers of Sublicenses to one or more Third Parties. Each such Sublicense will be consistent with the terms of this Agreement. Mirador will remain responsible for each such Third Party’s compliance with the applicable terms of this Agreement.

(b) All Sublicenses under the Penn License will be (x) issued in writing, (y) to the extent applicable, include all of the rights of Penn and require the performance of obligations due to Penn (and, if applicable, the U.S. Government under 35 U.S.C. §§200-212) contained in this Agreement and (z) shall include no less than the following terms and conditions:

(i) reasonable record keeping, audit and reporting obligations sufficient to enable Penn and Kira to reasonably verify the payments due to Penn and Kira under such Sublicense and to reasonably monitor such Sublicensee’s progress in Developing or Commercializing Licensed Components and Licensed Products, provided that such obligations shall be no less stringent than those provided in this Agreement for Mirador;

(ii) infringement and enforcement provisions that do not conflict with the restrictions and procedural requirements imposed on Mirador and do not provide greater rights to Sublicensee than as provided in Section 5.4 as applicable to Penn Patents;

(iii) confidentiality provisions with respect to Confidential Information of Kira and Penn consistent with the restrictions on Mirador in ARTICLE 9;

(iv) covenants by Sublicensee that are equivalent to those made by Mirador in Section 5.4 and Section 8.2.5;

18

(v) a requirement of indemnification of Penn by Sublicensee that is equivalent to the indemnification of Penn by Mirador under Section 7.1.3;

(vi) a requirement of obtaining and maintaining insurance by Sublicensee that is equivalent to the insurance requirements of Mirador under Section 7.2, including coverage under such insurance of Penn as provided in Section 7.2;

(vii) restriction on use of Penn’s names etc. consistent with Section 9.5;

(viii) a requirement of antidiscrimination by Sublicensee no less stringent than that provided in Section 10.2; and

(ix) a requirement that Penn is a third party beneficiary of such Sublicense. Any Sublicense that does not include all of the terms and conditions set forth in this Section 3.1.2(b) or which is not issued in accordance with the terms and conditions set forth in this Section 3.1.2, shall be considered null and void with no further notice from Kira.

(c) Within twenty (20) days after the execution of a Sublicense Document, Mirador shall provide a complete and accurate copy of such Sublicense Document to Kira, in the English Language. Kira shall have the right to provide a copy of such Sublicense Document to Penn. Kira’s receipt of a Sublicense Document, however, will constitute neither an approval nor disapproval of the Sublicense Document nor a waiver of any right of Kira or obligation of Mirador under this Agreement.

(d) Mirador shall provide an annual Sublicense Development Report on or before December 1 of each year during the Term (“SDR Report”) a form of which is attached hereto as Schedule 3.1.2.

** **

3.1.3. U.S. Government Rights. The License is expressly subject to all applicable provisions of any license to the United States Government executed by Penn and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. §§200-212, applicable governmental implementing regulations and the U.S. Government sponsored research agreement or other guidelines, including that products that result from intellectual property funded by the United States Federal Government that are sold in the United States be substantially manufactured in the United States. In the event that Mirador believes in good faith that substantial manufacture of such product is not commercially feasible in the United States and makes a request to Kira in writing to assist in obtaining a waiver of such requirement from the United States Government, then Kira shall, and shall make a request to Penn under the Penn License to, at the expense of Mirador, use reasonable efforts to assist in obtaining such waiver.

** **

**3.1.4. **Retained Rights. Notwithstanding the License, Penn retains the right under the Penn Patents to: (a) conduct education and research and clinical activities itself and (b) authorize non-commercial Third Parties to conduct educational and research and clinical activities. Penn also reserves the right to use, and to permit other entities to use, the mouse models listed in Schedule 3.1.4.

** **


19

** **

3.2. Technology Transfer.

** **

3.2.1. Initial Transfer. Within thirty (30) days after the Effective Date, except with respect to Physical Materials relating to the Licensed Compound, as set forth below, Kira will transfer to Mirador a copy of all Licensed Know-How existing as of the Effective Date, including (a) all pre-clinical, clinical and technical information (including raw data) that is Controlled by Kira or any of its Affiliates related to Licensed Components or Licensed Product, (b) Physical Materials, and (c) all other documentation (whether held in paper or electronic format and including copies of standard operating procedures or technical specifications), materials and other embodiments of Licensed Know-How Controlled by Kira or any of its Affiliates. Notwithstanding the foregoing, with respect to Physical Materials relating to the Licensed Compound, the Parties will discuss in good faith and agree upon an appropriate transfer date, which date will be no later than ninety (90) days following the Effective Date. Delivery of Physical Materials shall be Ex Works (Incoterms 2020) Kira’s or its designee’s facility(ies). Mirador shall be responsible for arranging pick-up, shipment, or further storage (as applicable), of the Physical Materials. Title to the Physical Materials shall not pass to Mirador until Kira’s receipt of payment pursuant to Section 4.2.

** **

3.2.2. Additional Transfers. Following the initial transfer described in Section 3.2.1, Kira will provide updates to Mirador once per Calendar Year regarding any newly acquired or generated Licensed Know-How, including information concerning any Licensed Products or Licensed Components, and improved procedures for synthesis or manufacture of Licensed Components or Licensed Products. During the Term, as reasonably requested by Mirador, Kira will promptly provide Mirador with any specific information or other Know-How included in the Licensed Technology. Kira will provide such information to Mirador within thirty (30) Business Days after Mirador’s request.

** **

3.2.3. Transfer of Manufacturing Know-How and Materials. Without limiting Kira’s other obligations under Section 3.2, immediately following the Effective Date, Kira will, or will cause any relevant Affiliate and any relevant Third Party (including any contract manufacturing organization engaged by Kira to Manufacture any Licensed Component or Licensed Product) to conduct a one-time Manufacturing technology transfer pursuant to this Section 3.2.3. Kira will (a) transfer to Mirador all Licensed Know-How that is necessary or reasonably useful to enable the Manufacture of each Licensed Component or Licensed Product, and not previously transferred to Mirador under this Agreement, by providing copies or samples of relevant documentation (whether held in paper or electronic format and including copies of standard operating procedures or technical specifications), materials and other embodiments of such Licensed Know-How, and by making available its, or the applicable Affiliate’s or Third Party’s, qualified technical personnel on a reasonable basis to consult with Mirador with respect to such Licensed Know-How, (b) at Mirador’s request, transfer to Mirador any Materials used by Kira or its Affiliates or Third Party subcontractors in the Manufacture of such Licensed Component or Licensed Product, excluding any commercially available, off-the-shelf Materials, and (c) assign all of Kira’s obligations and novate all of Kira’s rights to Mirador under the Third Party vendor and contractor agreement set forth in Schedule 3.2.3, in each case ((a) – (c)), to enable Mirador to Manufacture the Licensed Components and Licensed Products.

** **

3.2.4. Penn Mouse Models. Upon Mirador’s request for the Penn Mouse Models, Kira will use commercially reasonable efforts to execute a material transfer agreement between Penn and Kira, pursuant to which Penn will transfer the Penn Mouse Models (as defined in the Penn License) to Mirador, provided that (a) Penn contractually permits Kira to further transfer such Penn Mouse Models (as defined in the Penn License) to Mirador and (b) Mirador enters into a material transfer agreement with Kira on the same terms as the material transfer agreement between Penn and Kira.

** **

3.2.5. Costs and Expenses. With respect to the activities contemplated in this Section 3.2, within thirty (30) days after receipt of an invoice from Kira, (a) Mirador will reimburse Kira for all Out-of-Pocket Costs paid by Kira to a Third Party, including all Out-of-Pocket Costs paid by Kira to Penn to effectuate the transfer of Penn Mouse Models (as defined in the Penn License) to Mirador, (b) Kira will be responsible for all FTE Costs incurred by Kira for the first [***] ([***]) FTE hours, (c) Mirador will be responsible for all FTE Costs of Kira for FTE hours in excess of the cap set forth in clause (b), and (d) Mirador will be responsible for all FTE Costs and Out-of-Pocket Costs incurred by Mirador.

** **


20

** **

3.3. No Implied Licenses. Except as expressly provided in this Agreement, neither Party will be deemed to have granted the other Party (by estoppel, implication or otherwise) any licenses or other right with respect to any intellectual property.

** **

3.4. Exclusivity.

** **

3.4.1. Exclusivity Covenants. Subject to Section 3.4.2 and Section 3.4.3, on a country-by-country basis during the period commencing on the Effective Date and ending upon the expiration of all Royalty Terms in such country, except in the performance of its obligations or exercise of its rights under this Agreement, neither Kira nor any of its Affiliates will work independently or for or with, or grant any license to, any Third Party with respect to the development, manufacture, or commercialization of any compound, antibody, or product Directed To C5a or C5aR.

** **

3.4.2. Acquisition of a Distracting Product. Notwithstanding the provisions of Section 3.4.1, if Kira or its Affiliates acquire rights to develop or commercialize a product in the Field as the result of a merger, acquisition or combination with or of a Third Party other than a Change of Control where such Third Party is the acquired entity (each, an “Acquisition Transaction”) and, on the date of the closing of such Acquisition Transaction, such product is being developed or commercialized and such activities would, but for the provisions of this Section 3.4.2, constitute a breach of Section 3.4.1 (such product, a “Distracting Product”), Kira or such Affiliate will, within thirty (30) days after the closing of such Acquisition Transaction notify Mirador in writing of such acquisition and either:

(a) request that such Distracting Product be included in this Agreement on terms to be negotiated, in which case, the Parties will discuss the matter in good faith for a period of no less than sixty (60) days (or such longer period as may be agreed by the Parties) and, if unable to reach agreement on the terms on which such Distracting Product would be included hereunder within such period, Kira will elect to take the action specified in either clause (b) or (c) below; provided that the time periods specified in such clauses will be tolled for so long as the Parties are engaged in discussion under this clause (a);

(b) notify Mirador in writing that Kira or its Affiliate will Divest its rights to such Distracting Product, in which case, within two hundred seventy (270) days after the closing of the Acquisition Transaction, Kira or its Affiliate will Divest such Distracting Product; or

(c) notify Mirador in writing that it is ceasing all such development and commercialization activities with respect to the Distracting Product, in which case, within ninety (90) days after the other Party’s receipt of such notice, Kira and its Affiliates will cease all such activities.

During the discussion period under clause (a), prior to the time of divestiture pursuant to clause (b), or prior to the termination of activities pursuant to clause (c), as applicable, Kira and its Affiliates will use Commercially Reasonable Efforts to segregate all research, development, manufacturing or commercialization activities relating to the Distracting Product from Development, Manufacture and Commercialization with respect to Licensed Components or Licensed Products under this Agreement, including using Commercially Reasonable Efforts to ensure that no personnel involved in performing research, development, manufacturing or commercialization activities with respect to such Distracting Product have access to non-public plans or information relating to the Development, Manufacture or Commercialization of Licensed Components or Licensed Products under this Agreement (except that management personnel may review and evaluate plans and information regarding the Development and Commercialization of Licensed Products under this Agreement in connection with portfolio decision-making).

** **


21

** **

3.4.3. Change of Control. If there is a Change of Control involving Kira (where Kira is the acquired entity), the obligations of Section 3.4.1 will not apply to any product that is controlled by the relevant acquirer or its Affiliates and that exists prior to the closing of such Change of Control; provided that (a) Kira (and its Affiliates existing immediately prior to the effective date of such Change of Control) and the acquirer (and its Affiliates existing immediately prior to the effective date of such Change of Control) establish and enforce internal processes, policies, procedures and systems to segregate information relating to any such program from any Confidential Information related to the Licensed Components and Licensed Products under this Agreement, (b) the acquirer and its Affiliates existing immediately prior to the effective date of such Change of Control do not use or practice, directly or indirectly, any Licensed Technology existing immediately prior to the effective date of such Change of Control with respect to such product, and (c) no personnel who were employees or consultants of Kira (or its Affiliates existing immediately prior to the effective date of such Change of Control) at any time prior to or after the Change of Control will conduct any activities with respect to such product.

ARTICLE 4.

FINANCIAL PROVISIONS

** **

4.1. Up-Front Fee. Within seven (7) days following the Effective Date, Mirador will pay Kira a one-time up-front fee of Twelve Million Dollars ($12,000,000).

** **

4.2. Payment Upon Delivery of the Physical Materials. Within thirty (30) days following Kira’s delivery of the Physical Materials set forth in Schedule 1.114 pursuant to Section 3.2.1, Mirador will pay Kira Eight Million Dollars ($8,000,000). Notwithstanding the foregoing and Section 3.2.1, if Kira makes the Physical Materials set forth in Schedule 1.114 available for pick-up but Mirador does not coordinate or otherwise agree upon a delivery date that is within sixty (60) days of the Effective Date, then (a) in the event that the Physical Materials set forth in Schedule 1.114 are made available for pick-up on or before the date that is sixty (60) days after the Effective Date, the payment hereunder will be made no later than ninety (90) days after the Effective Date, and (b) in the event that the Physical Materials set forth in Schedule 1.114 are made available for pick-up on a date that is more than sixty (60) days after the Effective Date, the payment will be made no later than thirty (30) days after such Physical Materials are made available for pick-up.

22

** **

4.3. Milestone Payments.

** **

4.3.1. Licensed Antibody Research, Development & Regulatory Milestones. Mirador will pay Kira the milestone payments set forth in this Section 4.3.1 in accordance with the procedure set forth in Section 4.3.4 upon the first achievement of the relevant milestone event for a Licensed Antibody Product by Mirador or any of its Affiliates or Sublicensees. Each milestone payment set forth below is payable only once, regardless of the number of Licensed Antibody Products that achieve the relevant milestone event or the number of times a Licensed Antibody Product achieves the relevant milestone event.

Milestone Payment
Milestone Event 1st Indication 2nd Indication* 3rd Indication*
[***] $ [***] -- --
[***] $ [***] $ [***] $ [***]
[***] $ [***] $ [***] $ [***]
[***] $ [***] $ [***] $ [***]
[***] $ [***] -- --
[***] $ [***] -- --
TOTAL $ [***] $ [***] $ [***]
* For clarity, any Basket Study will be deemed to trigger the applicable development milestone for only one Indication.

** **

4.3.2. Licensed Compound Research, Development & Regulatory Milestones. Mirador will pay Kira the milestone payments set forth in this Section 4.3.2 in accordance with the procedure set forth in Section 4.3.4 upon the first achievement of the relevant milestone event for a Licensed Compound Product by Mirador or any of its Affiliates or Sublicensees. Each milestone payment set forth below is payable only once, regardless of the number of Licensed Compound Products that achieve the relevant milestone event or the number of times a Licensed Compound Product achieves the relevant milestone event.

Milestone Payment
Milestone Event 1st Indication 2nd Indication* 3rd Indication*
[***] $ [***] -- --
[***] $ [***] $ [***] $ [***]
[***] $ [***] $ [***] $ [***]
[***] $ [***] $ [***] $ [***]
[***] $ [***] -- --
[***] $ [***]
TOTAL $ [***] $ [***] $ [***]
* For clarity, any Basket Study will be deemed to trigger the applicable development milestone for only one Indication.

The cumulative amount of development milestone payments that would be payable by Mirador to Kira will not exceed One Hundred Eight Million Five Hundred Thousand Dollars ($108,500,000).

23

** **

4.3.3. Commercial Milestones. Mirador will pay Kira, on a Licensed Product-by-Licensed Product basis, the milestone payments set forth in this Section 4.3.3 in accordance with the procedure set forth in Section 4.3.4 upon the first achievement of the relevant milestone event by Mirador or its Affiliates or any Sublicensees. For the avoidance of doubt, the Annual Net Sales of Mirador, its Affiliates and Sublicensees for a Licensed Product will be aggregated in order to determine whether the milestone events below have been achieved. Each milestone payment set forth below, is payable only once per Licensed Product, regardless of the number of times a Licensed Product achieves such milestone event. The cumulative amount of commercial milestone payments that would be payable by Mirador to Kira will not exceed One-Hundred Seventy-Five Million Dollars ($175,000,000) for any one Licensed Product or Three-Hundred Fifty Million Dollars ($350,000,000) for all Licensed Products. For clarity, a Licensed Product may achieve multiple milestone events in the same Calendar Year.

Milestone Event Milestone Payment
[***] $ [***]
[***] $ [***]
[***] $ [***]
[***] $ [***]
[***] $ [***]
[***] $ [***]
[***] $ [***]
TOTAL $ 175,000,000

* *

4.3.4. Notice; Payment; Skipped Milestones. Mirador will provide Kira with written notice upon the achievement of each of the milestone events set forth in Section 4.3.1, Section 4.3.2, and Section 4.3.3, such written notice to be provided (a) with respect to any milestone event under Section 4.3.1 and Section 4.3.2, within twenty-five (25) days after such achievement and (b) with respect to any milestone event under Section 4.3.3, on or prior to the date of delivery of the royalty report under Section 4.4.9 for the Calendar Quarter in which such milestone event is first achieved. Following receipt of such written notice, Kira will promptly invoice Mirador for the applicable milestone and Mirador will make the appropriate milestone payment within twenty-five (25) days after achievement of such milestone event. Each milestone payment corresponding with the (i) first four (4) milestones as set forth in Section 4.3.1 and (ii) first four (4) milestones as set forth in Section 4.3.2, in each case ((i) and (ii)), are intended to be successive; if a Licensed Product is not required to undergo the event associated with any such milestone event, such skipped milestone will be deemed to have been achieved upon the achievement by such Licensed Product of the next successive milestone event. Payment for any such skipped milestone that is owed in accordance with the provisions of the foregoing sentence with respect to a given Licensed Product will be due concurrently with the payment for the next successive milestone event by such Licensed Product.

24

** **

4.4. Royalties.

4.4.1. Royalty Rates. Subject to Sections 4.4.2, 4.4.3, 4.4.4, 4.4.5, and 4.4.7, on a Licensed Product-by-Licensed Product basis, Mirador will pay Kira tiered royalties based on the aggregate Net Sales of each Licensed Product sold by Mirador, its Affiliates or Sublicensees in the Field in the Territory during a Calendar Year at the rates set forth in the table below. The obligation to pay royalties will apply only once with respect to the same unit of a Licensed Product.

Annual Net Sales (in Dollars) for such Licensed Product in the Territory Royalty Rates as a Percentage (%) of Net Sales
[***] [***]%
[***] [***] [***]%
[***] [***]%

4.4.2. Royalty Term. Mirador will pay royalties to Kira under this Section 4.4 on a Licensed Product-by-Licensed Product and a country-by-country basis during the Royalty Term for the applicable Licensed Product in the applicable country. Upon the expiration of the Royalty Term for a given Licensed Product in a given country, the license granted to Mirador under Section 3.1.1 will become fully-paid, perpetual and irrevocable with respect to such Licensed Product in such country.

** **

4.4.3. Reduction for Lack of Patent Coverage. If during any period within the applicable Royalty Term for a country, no Valid Claim of a Licensed Patent exists that Covers the composition of matter of such Licensed Product in such country, then the Net Sales of such Licensed Product in such country will be reduced by [***] percent ([***]%) for the remainder of the Royalty Term.

** **

4.4.4. Reduction for Competition. If during any Calendar Quarter during the Royalty Term for a Licensed Product in a given country, a Competitive Product with respect to such Licensed Product is approved by the applicable Regulatory Authority in such country and sold during such Calendar Quarter in such country then the Net Sales of such Licensed Product in such country (after any applicable reduction pursuant to Section 4.4.3) will be reduced by a percentage equal to the market share percentage of the Competitive Product by volume of units for purposes of calculating the royalty owed under Section 4.4.1 for the remainder of the Royalty Term. For example, if a Competitive Product gains thirty percent (30%) of the market share by volume of units, the royalty owed under Section 4.4.1 would be reduced by thirty percent (30%).

** **

4.4.5. Third Party Licenses. Mirador may deduct from the royalties payable to Kira under this Section 4.4, [***] percent ([***]%) of any Blocking Third Party Intellectual Property Costs paid by Mirador, its Affiliates or Sublicensees.

** **

4.4.6. Aggregate Limitation on Deductions. Notwithstanding Sections 4.4.3, 4.4.4, and 4.4.5, in no event will the combined effect of all reductions to the royalties payable to Kira under Sections 4.4.3, 4.4.4 and 4.4.5 (including as such reductions may be carried forward pursuant to the last proviso of this Section 4.4.6) reduce the royalty payable by Mirador to Kira under this Section 4.4 for any Licensed Product in any country during a Calendar Quarter to an amount less than (a) [***] percent ([***]%) of the amount that would otherwise be due under Section 4.4.1, but for such reductions, or (b) the royalties payable by Kira to Penn under the Penn License in such country in such Calendar Quarter, provided that, in each case ((a) and (b)), Mirador shall have the right to apply any uncredited reduction in royalties to any subsequent Calendar Quarter until such reduction is fully realized.

** **


25

** **

4.4.7. Limitation on Effective Royalty Rate. On a Licensed Product-by-Licensed Product basis, the effective Royalty Rate paid by Mirador in any Calendar Year, calculated as the sum of all commercial milestone payments under Section 4.3.3 (“Total Milestone Payments”) and all royalty payments made in such Calendar Year, divided by Net Sales of such Calendar Year ((commercial milestone payments + royalty payments)/Net Sales, the “Effective Royalty Rate”), shall not exceed [***] percent ([***]%) during the Royalty Term. If in any Calendar Year the Effective Royalty Rate calculated according to the payment schedule in Section 4.3.3 (“Unadjusted Effective Royalty Rate”) exceeds [***] percent ([***]%), a portion (or all, as applicable) of the Total Milestone Payments for such Calendar Year will be deferred to the following Calendar Year(s) such that the Effective Royalty Rate actually paid by Mirador to Kira (“Actual Effective Royalty Rate”) shall not exceed [***] percent ([***]%) in such Calendar Year, provided that the [***] percent ([***]%) maximal limit on the Actual Effective Royalty Rate continues to apply in each and all such following Calendar Year(s). If any such deferred Total Milestone Payment has not been recaptured for a Licensed Product at the later of (a) the expiration of the last-to-expire Valid Claim of a Licensed Patent that Covers the composition of matter of such Licensed Product in the United States and (b) the expiration of the United States regulatory exclusivity period for such Licensed Product (the later of (a) and (b) as the “End of Effective Royalty Accrual”), the smaller amount of (i) the difference between (A) the aggregate of Total Milestone Payments and royalty payments for such Licensed Product up to the End of Effective Royalty Accrual and (B) the product of [***] percent ([***]%) and aggregate Net Sales for such Licensed Product up to the End of Effective Royalty Accrual, and (ii) the deferred Total Milestone Payment for such Licensed Product at the End of Effective Royalty Accrual, will continue to be paid in the Calendar Year(s) subsequent to the End of Effective Royalty Accrual until the end of the Royalty Term of such Licensed Product, provided that the [***] percent ([***]%) maximal limit on the Actual Effective Royalty Rate continues to apply in each and all such subsequent Calendar Year(s). Any deferred Total Milestone Payment that has not been recaptured at the end of Royalty Term will be deemed fully paid.

** **

4.4.8. Penn Floor. Notwithstanding anything in this Agreement, including Section 4.4.3 through Section 4.4.7 or any allocation of Net Sales based on a Combination Product pursuant to Section 1.24 and Section 1.100, in no event shall any royalty reductions or allocation (as applicable) permitted thereunder result in Kira receiving royalty payments from Mirador under this Agreement in an amount that is less than the royalty payments payable by Kira to Penn under the Penn License (based on the terms set forth in the Third Amendment). In the event that the royalty reductions permitted pursuant to Section 4.4.3 through Section 4.4.7 would result in the occurrence of such an outcome, Mirador shall limit such royalty reductions to the extent necessary for Kira to receive an amount in royalty payments equal to the royalty payments payable by Kira to Penn under the Penn License, only to the extent and for so long as is necessary to ensure Kira’s royalty payments to Penn under the Penn License do not exceed Mirador’s royalty payments to Kira under this Agreement.

** **

4.4.9. Royalty Reports. Following the first sale of a Licensed Product giving rise to Net Sales and continuing for the remainder of the Royalty Term for such Licensed Product, within fifty (50) days after the end of each Calendar Quarter, Mirador will deliver a report to Kira specifying on a Licensed Product-by-Licensed Product and country-by-country basis: (a) number of each Licensed Product sold by Mirador, its Affiliates and Sublicensees in each country and the corresponding name of each such Licensed Product; (b) gross sales and Net Sales in the relevant Calendar Quarter; (c) to the extent such Net Sales include sales not denoted in US Dollars, a summary of the then-current exchange rate methodology(ies) used for the calculation of Net Sales in accordance with Section 4.6.2; (d) a specification of all deductions and their dollar value that were taken to calculate Net Sales; (e) a specification and calculation of all royalty reductions taken pursuant to Sections 4.4.3 through 4.4.7; and (f) royalties payable on such Net Sales. All royalty payments due under Section 4.4 for each Calendar Quarter will be due and payable within sixty (60) days after the end of each Calendar Quarter.

** **


26

** **

4.5. Kira In-License Agreements. Certain of the Licensed Technology Controlled by Kira as of the Effective Date was in-licensed or acquired by Kira under the agreements with Third Party licensors or sellers listed on Schedule 4.5 (such agreements other than the Penn License, the “Kira In-License Agreements”). Any payment obligations arising under the Kira In-License Agreements as a result of the Development, Manufacture and Commercialization of Licensed Components or Licensed Products prior to the Effective Date will be paid solely by Kira, except as otherwise agreed between the Parties in writing. Any payment obligations arising under the Penn License as a result of the Development, Manufacture and Commercialization of Licensed Components or Licensed Products will be paid solely by Kira.

** **

4.6. Payment Terms.

** **

4.6.1. Currency; Payment Method. All payments under this Agreement are expressed in U.S. Dollars and will be paid in U.S. Dollars, by wire transfer or Automated Clearing House (ACH) payment to an account designated by Kira (which account Kira may update from time to time in writing).

** **

4.6.2. Exchange. If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any calculations to be performed under this Agreement are denoted in a currency other than U.S. Dollars, such amounts will be converted to their U.S. Dollar equivalent using the closing exchange rate for the relevant currency for the applicable Calendar Quarter as reported in The Wall Street Journal, Internet Edition at www.wsj.com, as of the last day of the applicable reporting period (or, if unavailable on such date, the first date thereafter on which such rate is available), or a comparable publication mutually agreed by the Parties should the Wall Street Journal cease to exist.

** **

4.7. Withholding Tax. Where any sum due to be paid to Kira hereunder is subject to any withholding or similar tax, Mirador will pay such withholding or similar tax to the appropriate Governmental Authority and deduct the amount paid from the amount then due to Kira. Mirador will in a timely manner transmit to Kira an official tax certificate or other evidence of such withholding sufficient to enable Kira to claim such payment of taxes. The Parties will cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Mirador to Kira under this Agreement. Kira will provide Mirador any tax forms that may be reasonably necessary in order for Mirador not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. If (a) (i) either Party redomiciles to a new jurisdiction that is outside of the United States, (ii) either Party assigns or Sublicenses any rights or obligations under this Agreement to a Person that is domiciled in or redomiciles to a new jurisdiction outside of the United States, or (iii) either Party or such assignee or Sublicensee otherwise becomes subject to tax in a jurisdiction outside of the United States as a result of (A) the assignment or Sublicense by either Party of the rights and obligations under this Agreement, (B) the rights and obligations under this Agreement becoming attributable to a branch or permanent establishment by or of a Party of any assignee or Sublicensee, or (C) either Party or any assignee or Sublicensee having a presence or deemed presence in, having a present or former connection to, or becoming subject to net income tax in, a jurisdiction outside of the United States, and (b) as a result of any state of affairs described in clause (a), such Party or an assignee or Sublicensee is required by Applicable Law to withhold taxes in respect of any payment made to the other Party pursuant to this Agreement in excess of the amount that would have been required to be withheld if the state of affairs described in clause (a) had not occurred, then any amount payable by the affected Party to the other Party hereunder shall be increased to take into account such excess withholding taxes as may be necessary so that, after making all required withholding, such other Party receives an amount it would have received had the state of affairs described in clause (a) not occurred.

27

** **

4.8. Records; Audits. Mirador will keep and maintain accurate and complete records regarding the calculation of any milestone payments and royalties (including Net Sales) during the five (5) preceding Calendar Years. Kira will keep accurate and complete records regarding all Out-of-Pocket Costs and FTE Costs incurred in connection with the performance of the technology transfer activities in sufficient detail to confirm the accuracy of any payments required under this Agreement, covering the five (5) preceding Calendar Years. Upon fifteen (15) days’ prior written notice from the other Party (the “Auditing Party”), the Party required to maintain such records (as applicable, the “Audited Party”) will permit an independent certified public accounting firm of internationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine the relevant books and records of the Audited Party and its Affiliates, as may be reasonably necessary to verify the calculation of milestone payments and royalties (including Net Sales) calculated by Mirador in accordance with ARTICLE 4 or the FTE Costs or Out-of-Pocket Costs reported by Kira in accordance with Section 2.2.3 and 3.2. An examination by the Auditing Party under this Section 4.8 will occur not more than once in any Calendar Year and will be limited to the pertinent books and records for any Calendar Year ending not more than sixty (60) months before the date of the request. The accounting firm will be provided access to such books and records at the Audited Party’s facility or facilities where such books and records are normally kept and such examination will be conducted during the Audited Party’s normal business hours. The Audited Party may require the accounting firm to sign a customary non-disclosure agreement before providing the accounting firm access to its facilities or records. Upon completion of the audit, the accounting firm will provide both Parties a written report disclosing whether the payments calculated by Mirador or the FTE Costs or Out-of-Pocket Costs submitted by Kira, as applicable, are correct or incorrect and the specific details concerning any discrepancies. No other information will be provided to the Auditing Party. If the report or information submitted by the Audited Party resulted in an underpayment or overpayment, the Party owing the underpaid or overpaid amount will promptly pay such amount to the other Party. The costs and fees of any audit conducted by the Auditing Party under this Section 4.8 will be borne by the Auditing Party, unless such audit reveals an underpayment of amounts owed to the Auditing Party or an overpayment of amounts owed by the Auditing Party of more than five percent (5%) of the amount that was owed by the Audited Party or owed to the Audited Party, as applicable, with respect to the relevant period, in which case, the Audited Party will reimburse the Auditing Party for the reasonable expense incurred by the Auditing Party in connection with the audit.

ARTICLE 5.

INTELLECTUAL PROPERTY

** **

5.1. Ownership of Agreement Technology. For purposes of determining ownership under this Section 5.1, inventorship will be determined in accordance with United States patent laws (regardless of where the applicable activities occurred).

** **

5.1.1. Kira Agreement Technology. As between the Parties, Kira will be the sole owner of any Know-How discovered, developed, invented or created solely by Kira or its Affiliates or Third Parties acting on its or their behalf, in each case, in the performance of activities under this Agreement (“Kira Agreement Know-How”) and any Patents that Cover Kira Agreement Know-How (“Kira Agreement Patents” and together with the Kira Agreement Know-How, the “Kira Agreement Technology”), and will retain all of its rights thereto, subject to any rights or licenses expressly granted by Kira to Mirador under this Agreement. Kira will promptly disclose to Mirador in writing, and will cause its Affiliates to so disclose, the discovery, development, invention or creation of any Kira Agreement Know-How or Kira Agreement Patent.

28

** **

5.1.2. Mirador Agreement Technology. As between the Parties, Mirador will be the sole owner of any Know-How discovered, developed, invented or created solely by Mirador or its Affiliates or Third Parties acting on its or their behalf, in each case, in the performance of activities under this Agreement (“Mirador Agreement Know-How”) and any Patents that Cover Mirador Agreement Know-How (“Mirador Agreement Patents” and together with the Mirador Agreement Know-How, the “Mirador Agreement Technology”), and will retain all of its rights thereto, subject to any rights or licenses expressly granted by Mirador to Kira under this Agreement.

** **

5.2. Prosecution and Maintenance of Patents.

** **

5.2.1. Kira Agreement Patents. As between the Parties, Kira will have the sole right, at Kira’s expense, to control the Prosecution and Maintenance of the Patents within the Kira Agreement Patents that are not Licensed Patents.

** **

5.2.2. Mirador Agreement Patents. As between the Parties, Mirador will have the sole right, at Mirador’s expense, to control the Prosecution and Maintenance of the Mirador Agreement Patents.

** **

5.2.3. Licensed Patents. As between the Parties, Mirador will have the first right, at Mirador’s expense, to control the Prosecution and Maintenance of the Licensed Patents in the name of Kira or Penn, as applicable. Mirador agrees to keep Kira reasonably informed with respect to such Prosecution and Maintenance, provide Kira with copies of material correspondence and filings relating thereto and consult in good faith with Kira regarding such matters. To the extent a Licensed Patent covers any other Kira products, Mirador will accept Kira’s reasonable comments with regard to prosecution of such Licensed Patents; provided that, Mirador is not obligated to accept any comments that may have a negative commercial impact on any Licensed Product. If Mirador decides to abandon a Licensed Patent, Mirador will provide Kira with notice at least forty-five (45) days prior to the earlier of the date such abandonment would become effective and any applicable filing deadline. Following such notice, Kira may elect, upon written notice to Mirador, to control the Prosecution and Maintenance of such Patent at its own expense in Kira’s name. Upon such election, Mirador will cooperate and assist in transitioning the Prosecution and Maintenance of such Patent to Kira, Kira agrees to keep Mirador reasonably informed with respect to such Prosecution and Maintenance and consult in good faith with Mirador regarding such matters. For clarity, Mirador acknowledges that Penn has certain rights to control the Prosecution and Maintenance of Penn Patents, and Mirador’s rights hereunder with respect to Penn Patents are subject to the Penn License. Kira shall provide to Mirador any rights of Kira with respect to the Prosecution and Maintenance of any Penn Patents by Penn. With respect to any costs and expenses for the Prosecution and Maintenance of Penn Patents by Penn for which Kira is obligated to pay or reimburse Penn, Kira shall have the right to invoice Mirador for such costs and expenses and Mirador shall pay such invoice within thirty (30) days of Mirador’s receipt of such invoice.

** **

5.2.4. Cooperation. Mirador and Kira will obtain the cooperation of their respective employees or obligated Third Parties that are inventors in the Prosecution and Maintenance directed to any inventions that may arise hereunder.

29

** **

5.3. Defense of Claims Brought by Third Parties. If any Third Party brings a claim or otherwise asserts that a Licensed Product or Licensed Component infringes such Third Party’s Patent or misappropriates such Third Party’s Know-How (each, a “Third-Party Infringement Claim”), the Party first having notice of the claim or assertion will promptly notify the other Party in writing. Subject to Section 7.1 and this Section 5.3, Mirador will have the sole right to undertake and control the defense or settlement of any Third-Party Infringement Claim using counsel of its choice, at its expense. Subject to Section 7.1, if Kira is named as a defendant in any such Third-Party Infringement Claim, Kira will have the right to fully participate in such defense and settlement with its own counsel, at its expense. Subject to Section 7.1, Mirador will not enter into any settlement of any Third-Party Infringement Claim that is instituted or threatened to be instituted against Kira without Kira’s prior written consent, which will not be unreasonably withheld, conditioned or delayed; provided that*,* such consent will not be required if such settlement includes a release of all liability in favor of Kira. As requested by Mirador, Kira will provide reasonable cooperation and assistance to Mirador in connection with Mirador’s control of the defense or settlement of a Third-Party Infringement Claim. Such cooperation and assistance will include executing all necessary and proper documents and taking such actions as will be appropriate to allow Mirador to control the defense and settlement of such Third-Party Infringement Claim. Subject to Section 7.1, Mirador will reimburse Kira for the reasonable Out-of-Pocket Costs incurred by Kira in providing such assistance and cooperation; *provided *that Mirador will have no obligation to reimburse Kira for any such Out-of-Pocket Costs incurred for legal counsel representing Kira in such matter if Kira exercises its right to participate in the defense and settlement of a Third-Party Infringement Claim with its own counsel. Mirador will keep Kira reasonably informed of the progress of any Third-Party Infringement Claim. To the extent reasonable, both Parties will cooperate in good faith to (a) ensure that Mirador has the ability to continue to Commercialize Licensed Products and (b) avoid or minimize any additional royalties payable to Third Parties on Licensed Products.

** **

5.4. Enforcement of Patents Against Competitive Infringement.

** **

5.4.1. Duty to Notify of Competitive Infringement. If either Party learns of an infringement, unauthorized use, misappropriation or threatened infringement by a Third Party with respect to any Licensed Technology by reason of the making, using, offering to sell, selling, importing or other exploitation of a pharmaceutical compound or product that would be competitive with a Licensed Component or Licensed Product in the Territory (a “Competitive Infringement”), such Party will promptly notify the other Party in writing and will provide such other Party with available information regarding such Competitive Infringement.

** **

5.4.2. Enforcement.

(a) Mirador will have the first right, but not the obligation, to institute, prosecute, and control a Proceeding with respect to any Competitive Infringement by counsel of its own choice, at its own expense. If Mirador fails to initiate a Proceeding within sixty (60)*** ***days after written notice of such Competitive Infringement is first provided by a Party under Section 5.4.1, Kira will have the right to initiate and control a Proceeding with respect to such Competitive Infringement by counsel of its own choice, at its own expense and Mirador will have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, that if Mirador notifies Kira during such sixty (60)-day period that it is electing in good faith not to institute any Proceeding against such Competitive Infringement for strategic reasons, Kira will not have the right to initiate and control any Proceeding with respect to such Competitive Infringement.

(b) The Party prosecuting and controlling any such Proceeding will (i) keep the other Party reasonably apprised of the progress of such Proceeding, (ii) reasonably consider the other Party’s comments with respect to the conduct of such Proceeding and (iii) not enter into a settlement, consent judgment or other voluntary final disposition of a Proceeding that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue, or similar immunity that has an adverse effect on the other Party’s rights hereunder without the other Party’s prior written consent, not to be unreasonably withheld; provided, that the foregoing restriction on granting a license under this clause (iii) will not apply with respect to any Sublicense granted by Mirador.

30

(c) Notwithstanding the foregoing, Mirador acknowledges that Penn may have certain rights regarding Competitive Infringement under the Penn License, and accordingly any rights granted under this Section 5.4 by Kira to Mirador are hereby qualified by any applicable rights of, or obligations owed to, Penn under the Penn License.

** **

5.4.3. Joinder.

(a) If a Party initiates a Proceeding in accordance with this Section 5.4, the other Party agrees to be joined as a party plaintiff where necessary for standing purposes and to give the first Party reasonable assistance and authority to file and prosecute the Proceeding. Subject to Section 5.4.4, the costs and expenses of each Party incurred pursuant to this Section 5.4.3(a) will be borne by the Party initiating such Proceeding.

(b) If one Party initiates a Proceeding in accordance with this Section 5.4, the other Party may join such Proceeding as a party plaintiff where necessary for such other Party to seek lost profits with respect to such infringement.

** **

5.4.4. Share of Recoveries. Any damages or other monetary awards recovered with respect to a Proceeding brought pursuant to this Section 5.4 will be shared as follows:

(a) subject first to Section 5.4.3(a), the amount of such recovery will first be applied to the Parties’ reasonable Out-of-Pocket Costs incurred in connection with such Proceeding (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses); then

(i) any remaining proceeds constituting direct or actual damages for acts of infringement will be paid to, or retained by, the Party initiating such Proceeding; provided that, if Mirador is the initiating Party, such amounts will be included in Net Sales for the Calendar Quarter in which such amounts are received by Mirador; and

(ii) any remaining proceeds constituting punitive or treble damages will be allocated between the Parties as follows: the Party initiating the Proceeding will retain eighty percent (80%) of such proceeds and the other Party will receive twenty percent (20%) of such proceeds.

** **

5.4.5. Settlement. Notwithstanding anything to the contrary under this ARTICLE 5, neither Party may enter a settlement, consent judgment or other voluntary final disposition of a suit under this ARTICLE 5 that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue or similar immunity under a Patent Controlled by the other Party or its Affiliates without first obtaining the written consent of the Party that Controls the relevant Patent; provided, that the foregoing restriction on granting a license will not apply with respect to any Sublicense granted by Mirador.

** **

5.5. Other Infringement.

** **

5.5.1. Patents Solely Owned by Kira. Kira will retain all rights to pursue an infringement of any Licensed Patent solely owned by Kira or its Affiliate that is not a Competitive Infringement and Kira will retain all recoveries with respect thereto.

** **


31

** **

5.5.2. Patents Solely Owned by Mirador. Mirador will retain all rights to pursue an infringement of any Patent solely owned by Mirador and Mirador will retain all recoveries with respect thereto.

** **

5.6. Patent Listing. Mirador will have the sole right, but not the obligation, to submit to all applicable Regulatory Authorities patent information pertaining to each applicable Licensed Product pursuant to 21 U.S.C. § 355(b)(1)(G), any similar statutory or regulatory requirement enacted in the future regarding pharmaceutical products, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction.

** **

5.7. Patent Term Extension. Mirador will have the sole right to obtain patent term restoration in any country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. § 156, where applicable to a Licensed Product. Mirador will determine which relevant patents will be extended (including by filing supplementary protection certificates and any other extensions that are now or in the future become available). Kira will abide by Mirador’s determination and cooperate, as reasonably requested by Mirador, in connection with the foregoing (including by providing appropriate information and executing appropriate documents).

** **

5.8. Recording. If Mirador deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority in one or more jurisdictions in the Territory, Kira will reasonably cooperate to execute and deliver to Mirador any documents accurately reflecting or evidencing this Agreement that are necessary or desirable, in Mirador’s reasonable judgment, to complete such registration or recordation. Mirador will reimburse Kira for all reasonable Out-of-Pocket Costs, including attorneys’ fees, incurred by Kira in complying with the provisions of this Section 5.8.

** **

5.9. Unitary Patent System. The Party Prosecuting and Maintaining a Patent in Europe pursuant to Section 5.2 will have the exclusive right to opt-in or opt-out of the Europe Unitary Patent System for such Patent. For clarity, “to opt-in or opt-out” refers to both the right to have or have not a European patent application or an issued European patent registered to have unitary effect within the meaning of Regulation (EU) No 1257/2012 of December 17, 2012 as well as the Agreement on a Unified Patent Court as of February 19, 2013; and to the right to opt-in or opt-out from the exclusive competence of the Unified Patent Court in accordance with Article 83(3) of that Agreement on a Unified Patent Court. Without limiting the generality of the foregoing, unless a Party or its Affiliate has expressly opted in to the Europe Unitary Patent System with respect to a given Patent, the other Party will not initiate any action with respect to such Patent under the Europe Unitary Patent System without such Party’s prior written approval, such approval to be granted or withheld in such Party’s sole discretion.

** **

5.10. Trademarks. As between the Parties, all trademarks and trade dress rights used in connection with the Commercialization of the Licensed Products in the Field in the Territory will be owned exclusively by Mirador.

32

** **

5.11. Bankruptcy.

** **

5.11.1. All rights and licenses now or hereafter granted by Kira to Mirador under or pursuant to this Agreement, including, for the avoidance of doubt, the licenses granted to Mirador pursuant to Section 3.1, are, for all purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined in the U.S. Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to Kira, Kira agrees that Mirador, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. Without limiting the generality of the foregoing, the Parties intend and agree that any sale of Kira’s assets under Section 363 of the Bankruptcy Code shall be subject to Mirador’s rights under Section 365(n), that Mirador cannot be compelled to accept a money satisfaction of its interests in the intellectual property licensed pursuant to this Agreement, and that any such sale therefore may not be made to a purchaser “free and clear” of Mirador’s rights under this Agreement and Section 365(n) without the express, contemporaneous consent of Mirador. Further, each Party agrees and acknowledges that all payments by Mirador to Kira hereunder constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder. If (a) a case under the U.S. Bankruptcy Code is commenced by or against Kira, (b) this Agreement is rejected as provided in the U.S. Bankruptcy Code, and (c) Mirador elects to retain its rights hereunder as provided in Section 365(n) of the U.S. Bankruptcy Code, then Kira (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) will:

(i) provide Mirador with all such intellectual property (including all embodiments thereof) within the Licensed Technology held by Kira and such successors and assigns, or otherwise available to them, immediately upon Mirador’s written request.; and

(ii) not interfere with Mirador’s rights under this Agreement, or any agreement supplemental hereto, to such intellectual property (including such embodiments) with the Licensed Technology, including any right to obtain such intellectual property (or such embodiments) within the Licensed Technology from another entity, to the extent provided in Section 365(n) of the U.S. Bankruptcy Code.

** **

5.11.2. All rights, powers and remedies of Mirador provided herein are in addition to and not in substitution for any other rights, powers and remedies now or hereafter existing at law or in equity (including the U.S. Bankruptcy Code) in the event of the commencement of a case under the U.S. Bankruptcy Code with respect to Kira.

ARTICLE 6.

REPRESENTATIONS AND WARRANTIES

** **

6.1. Representations and Warranties of Mirador. Mirador hereby represents and warrants to Kira, as of the Effective Date, that:

** **

6.1.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization;

** **

6.1.2. it (a) has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;

** **

6.1.3. this Agreement has been duly executed and delivered on behalf of Mirador, and constitutes a legal, valid and binding obligation, enforceable against Mirador in accordance with the terms hereof;

** **

6.1.4. the execution, delivery and performance of this Agreement by Mirador will not constitute a default under or conflict with any agreement, instrument, obligation or understanding, oral or written, to which either entity is a party or by which either entity is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; and

33

** **

6.1.5. it has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities required to be obtained by it in connection with the execution and delivery of this Agreement.

** **

6.2. Representations and Warranties of Kira. Kira hereby represents and warrants to Mirador, that as of the Effective Date except as set forth in the corresponding section of Schedule 6.2:

** **

6.2.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization;

** **

6.2.2. it (a) has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;

** **

6.2.3. it has the requisite resources and expertise to perform its obligations hereunder;

** **

6.2.4. this Agreement has been duly executed and delivered on behalf of Kira, and constitutes a legal, valid and binding obligation, enforceable against it in accordance with the terms hereof;

** **

6.2.5. the execution, delivery and performance of this Agreement by Kira will not constitute a default under or conflict with any agreement, instrument, obligation or understanding, oral or written, to which it is a party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it;

** **

6.2.6. it has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities required to be obtained by it in connection with the execution and delivery of this Agreement;

** **

6.2.7. the Licensed Technology constitutes all of the Patents and Know-How Controlled by Kira or its Affiliates that are necessary or reasonably useful to Exploit Licensed Components and Licensed Products in the Field in the Territory;

** **

6.2.8. Kira or its Affiliate is the sole and exclusive owner or, to its knowledge, exclusive licensee of the Licensed Patents, all of which is, (a) with respect to any in-licensed Licensed Patents, to Kira’s knowledge, free and clear of any liens, charges and encumbrances, or (b) with respect to Licensed Patents owned by Kira or its Affiliate, free and clear of any liens, charges and encumbrances and, with respect to all Licensed Patents (including those referenced in (a) and (b) above), as of the Effective Date, neither any license granted by Kira or its Affiliates to any Third Party, nor any agreement between any Third Party and Kira or its Affiliates, conflicts with the licenses or other rights granted to Mirador hereunder;

** **

6.2.9. Kira is entitled to grant all rights and licenses (or sublicenses, as the case may be) it purports to grant to Mirador under this Agreement;

** **

6.2.10. neither Kira, nor any of its Affiliates, Control any backups, improvements, sequences, or other modifications relating to the Licensed Antibody or otherwise Directed To C5a or C5aR that have not been disclosed to Mirador as of the Effective Date, including in connection with antibody campaign described in United States patent number 11,274,146 and United States patent application number 18/696,768;

** **


34

** **

6.2.11. Kira has disclosed to Mirador in Schedule 1.87 all Licensed Patents existing as of the Effective Date, and such disclosure indicates whether each such Patent is owned by Kira or its Affiliates or licensed by Kira from a Third Party and if so licensed, identifies the licensor or sublicensor from which the Patent is licensed and Kira has provided Mirador with a true and complete copy of each such license agreement;

** **

6.2.12. (a) (i) the Licensed Patents (other than Penn Patents) are subsisting and, to Kira’s knowledge, are, or, upon issuance, will be, valid and enforceable patents, and (ii) the Penn Patents, to Kira’s knowledge, are subsisting and are, or upon issuance will be, valid and enforceable patents, and (b) no Third Party has challenged in writing to Kira, and Kira is not aware of any challenge by a Third Party (in writing or otherwise) to, the scope, validity or enforceability of such Penn Patents (including by way of example through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority);

** **

6.2.13. to its knowledge, no Third Party is infringing or threatening to infringe any of the Licensed Patents or misappropriating or threatening to misappropriate any Licensed Know-How;

** **

6.2.14. it has complied with Applicable Law in all material respects, including any disclosure requirements of the United States Patent and Trademark Office or any analogous foreign Governmental Authority, in connection with the Prosecution and Maintenance of the Licensed Patents and has timely paid all filing and renewal fees payable with respect to any such Patents for which it controls Prosecution and Maintenance;

** **

6.2.15. it has obtained assignments from the inventors of all inventorship rights relating to the Licensed Patents solely owned by Kira or its Affiliates, and all such assignments of inventorship rights relating to such Patents are valid and enforceable;

** **

6.2.16. to Kira’s knowledge, with respect to Licensed Patents that have been licensed to Kira or its Affiliates by a Third Party, (a) such Third Party has obtained assignments from the inventors of all inventorship rights relating to such Licensed Patents, and (b) all such assignments of inventorship rights relating to such Patents are valid and enforceable;

** **

6.2.17. there are no chemical compounds, biological materials, including Clinical Trial samples, cell lines, lipids, assays, viruses and vectors, raw materials, kits, and ingredients for manufacturing or testing Licensed Components or Licensed Products, or other materials in the possession or Control of a Third Party that would be Materials if they were in Kira’s possession or Control;

** **

6.2.18. there are no physical samples of Licensed Antibody(ies), cell lines used to manufacture Licensed Antibody(ies), Licensed Compound(s) or Licensed Product(s), and any drug substance, drug product or other tangible materials relating to the foregoing in the possession or Control of a Third Party that would be Physical Materials if they were in Kira’s possession or Control;

** **


35

** **

6.2.19. except for the Kira In-License Agreements and the Penn License, there is no agreement between Kira or any of its Affiliates and any Third Party pursuant to which Kira or its Affiliate has acquired Control of any of the Licensed Technology. All Kira In-License Agreements and the Penn License are in full force and effect and have not been modified or amended other than by amendments disclosed to Mirador prior to the Effective Date. Kira has provided true and complete copies of all Kira In-License Agreements and the Penn License to Mirador. Neither Kira nor its Affiliates nor, to its knowledge, the Third Party licensor in any Kira In-License Agreement or the Penn License is in material breach of, or in default with respect to a material obligation under, any Kira In-License Agreement or the Penn License, and neither such party has claimed that the other party is in material breach of, or in default with respect to a material obligation under, any Kira In-License Agreement or the Penn License;

** **

6.2.20. Kira and its Affiliates have taken commercially reasonable measures consistent with industry practices to protect the secrecy, confidentiality and value of all Licensed Know-How that constitutes trade secrets under Applicable Law (including requiring all employees, consultants and independent contractors to execute binding and enforceable agreements requiring all such employees, consultants and independent contractors to maintain the confidentiality of such Licensed Know-How) and, to Kira’s knowledge, such Licensed Know-How has not been used, disclosed to or discovered by any Third Party except pursuant to such confidentiality agreements and there has not been a breach by any party to such confidentiality agreements;

** **

6.2.21. no Licensed Technology is subject to any funding agreement with any government or governmental agency;

** **

6.2.22. to its knowledge, the Exploitation by Mirador (or their respective Affiliates or Sublicensees) of the Licensed Components and Licensed Products, as contemplated under this Agreement as of the Effective Date, does not and will not infringe any issued Patent of any Third Party or, if and when issued, any claim within any Patent application of any Third Party;

** **

6.2.23. to its knowledge, the conception, development, and reduction to practice of the Licensed Technology have not constituted or involved the misappropriation of any Know-How of any Third Party, and the practice of the Licensed Know-How in the Exploitation by Kira or its Affiliates of a Licensed Component or Licensed Product prior to the Effective Date has not misappropriated any Know-How of any Third Party;

** **

6.2.24. there are no judgments or settlements against or owed by Kira or its Affiliates or, to its knowledge, pending or threatened claims or litigation, in either case relating to the Licensed Technology;

** **

6.2.25. there is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to its knowledge, threatened against Kira, any of its Affiliates or any Third Party, in each case in connection with the Licensed Technology, the Licensed Components, the Licensed Products, or otherwise relating to the transactions contemplated by this Agreement;

** **

6.2.26. Kira has not employed (and, to its knowledge, has not used a contractor or consultant that has employed) any Person debarred by the FDA (or subject to a similar sanction of EMA or foreign equivalent), or any Person that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA or foreign equivalent), in any capacity in connection with this Agreement;

36

** **

6.2.27. with respect to any Licensed Technology, Licensed Component or Licensed Product or activities to be performed by Kira in connection with this Agreement, Kira has not taken any action directly or indirectly to unlawfully offer, promise, or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted any such unlawful payment;

** **

6.2.28. to its knowledge, except to the extent permissible under United States law, neither Kira nor any of its Affiliates has, on its own behalf or in acting on behalf of any other Person, directly or indirectly engaged in any transaction, or has otherwise dealt with, any country or Person targeted by the United States, Europe or other relevant economic sanctions laws in connection with any activities contemplated by this Agreement; and

** **

6.2.29. Kira has neither received from Penn, nor used, the Penn Mouse Models (as defined in the Penn License) pursuant to the Penn License.

** **

6.3. Kira Covenants. Kira hereby covenants to Mirador that, except as expressly permitted under this Agreement:

** **

6.3.1. Kira will, and will require its Affiliates and subcontractors to, comply with Applicable Law and accepted pharmaceutical industry business practices in conducting its activities hereunder, including (a) to the extent applicable to Kira or its Affiliates or subcontractor, the FD&C Act, the Anti-Kickback Statute (42 U.S.C. 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. 1320a-7a), the False Claims Act (31 U.S.C. 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes and the regulations issued by the FDA, consistent with the ‘Compliance Program Guidance for Pharmaceutical Manufacturers’ published by the Office of Inspector General, U.S. Department of Health and Human Services, (b) the applicable laws and regulations of the countries where it operates, including anti-bribery and anti-corruption laws, accounting and record keeping laws and laws relating to interactions with healthcare professionals or healthcare providers and Government Officials and (c) where appropriate GMP, GCP and GLP (or similar standards);

** **

6.3.2. Kira will maintain and not breach, and will cause its Affiliates to maintain and not breach, any Kira In-License Agreements and the Penn License;

** **

6.3.3. Kira will promptly notify Mirador in writing of any material breach by Kira or its Affiliate or a Third Party of any Kira In-License Agreements or the Penn License, and will promptly notify Mirador in writing if Kira or its Affiliate sends or receives a notice of material breach of any Kira In-License Agreements or the Penn License, and in the event of a breach by Kira or its Affiliate, will permit Mirador to cure such breach on Kira’s or its Affiliate’s behalf upon Mirador’s request;

** **

6.3.4. Kira will not, and will cause its Affiliates not to, amend, modify or terminate any Kira In-License Agreement or the Penn License in a manner that would adversely affect Mirador’s rights hereunder without first obtaining Mirador’s written consent, which consent may be withheld in Mirador’s sole discretion;

** **

6.3.5. neither Kira nor any of its Affiliates will effect any corporate restructuring or enter into any new agreement or otherwise obligate itself to any Third Party or Affiliate, or amend an existing agreement with a Third Party or Affiliate, in each case, in a manner that restricts, limits, or encumbers the rights granted to Mirador under this Agreement or the obligations of Kira or its Affiliates under this Agreement;

** **

6.3.6. Kira will negotiate in good faith with Mirador and Penn in order to obtain certain reasonable amendments to the Penn License during the Term;

37

** **

6.3.7. Kira will not, and will cause its Affiliates not to (a) license, sell, assign or otherwise transfer to any Person any Licensed Technology (or agree to do any of the foregoing), (b) negotiate with, offer to, or grant any license to any Person, or (c) incur or permit to exist, with respect to any Licensed Technology, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other restriction (including in connection with any indebtedness), in each case ((a) through (c)), that would conflict with, limit, impair or restrict the rights and licenses granted to Mirador hereunder or would cause any Licensed Technology to cease to be Controlled by Kira; provided that, in the case of any of the scenarios contemplated under Section 3.4.2 and 3.4.3, Kira will not be deemed in breach of this Section 6.3.7 so long as Kira complies with the terms and conditions set forth therein;

** **

6.3.8. Kira will be, will cause its Affiliates to be, in compliance with all applicable economic sanctions, import, and export control laws, regulations, and orders;

** **

6.3.9. with respect to any Licensed Technology, Licensed Component, Licensed Product, payments or activities performed by Kira in connection with this Agreement, Kira will not take any action to unlawfully offer, promise, or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper advantage, and will not accept any such unlawful payment;

** **

6.3.10. Kira will not, and will cause its Affiliates not to, engage with or engage in any transaction, or otherwise deal with, any country or Person targeted by the United States, Europe or other relevant economic sanctions laws in connection with any activities contemplated under this Agreement;

** **

6.3.11. no later than sixty (60) days following the Effective Date, Kira shall deliver to Mirador a copy of its filing submitted for registration of the licenses granted by Kira Suzhou to Kira under that certain License Agreement by and between Kira and Kira Suzhou entered into as of July [●], 2026 (the “Intercompany License Agreement”) as a technology export contract before the Ministry of Commerce of the People’s Republic of China (MOFCOM) within the time limits stipulated thereunder (to the extent required, or written documentation confirming that such registration is not required);

** **

6.3.12. Kira will not (a) terminate the Intercompany License Agreement, (b) amend the Intercompany License Agreement in a manner that would adversely affect Mirador’s rights hereunder or (c) take any other action with respect to the Intercompany License Agreement that would adversely affect Mirador’s rights hereunder, in each case (a)-(c), without first obtaining Mirador’s written consent, which consent may be withheld in Mirador’s sole discretion; and

** **

6.3.13. Kira will be, as between the Parties, solely responsible to ensure Compliance by it and its Affiliates.

** **

6.4. Mirador Covenants. Mirador hereby covenants to Kira that, except as expressly permitted under this Agreement:

** **

6.4.1. Mirador will comply with all Applicable Laws that apply to its activities or obligations under this Agreement. For example and without limiting the foregoing obligation to comply with all Applicable Laws, Mirador will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States government and/or written assurances by Mirador that Mirador will not export data or commodities to certain foreign countries without prior approval of the agency;

** **


38

** **

6.4.2. Mirador will not grant a security interest in the License or this Agreement without Penn’s prior written consent; and

** **

6.4.3. At no time during the Term shall Dr. Wenchao Song or his family members (individually or in the aggregate) own or control a majority of the capital securities of Mirador, provided that this provision will remain in effect for so long as Dr. Wenchao Song is subject to the requirements of the Penn Patent Policy or applicable equivalent;

** **

6.5. Disclaimer. Except as otherwise expressly set forth in this Agreement, neither Party nor its Affiliates makes any representation or extends any warranty of any kind, either express or implied, including any warranty of merchantability or fitness for a particular purpose. Mirador and Kira understand that each Licensed Product is the subject of ongoing Research and Development and that neither Party can assure the safety, usefulness or commercial or technical viability of any Licensed Product. Furthermore, Mirador understands that the physical materials and materials are provided “as is” and that Kira makes no representation or warranty, and hereby disclaims any and all representations and warranties, either express or implied, including any warranty of merchantability or fitness for a particular purpose, with respect to the physical materials and materials.

ARTICLE 7.

INDEMNIFICATION; INSURANCE; LIMITATIONS

** **

7.1. Indemnification.

** **

7.1.1. Indemnification by Mirador. Subject to Section 7.1.3, Mirador will indemnify Kira, its Affiliates, and its and its Affiliates’ employees, officers and directors (each, a “Kira Indemnified Party”) from and against any liability, loss, damage or expense (including reasonable attorneys’ fees and expenses) (collectively, “Liability”) that the Kira Indemnified Party may incur or otherwise be required to pay to one or more Third Parties in connection with any Third Party suit, investigation, claim or demand resulting from or arising out of:

(a) the Exploitation of any Licensed Component or Licensed Product by, on behalf of, or under the authority of, Mirador (other than by any Kira Indemnified Party);

(b) the breach by Mirador of any of its representations, warranties or covenants set forth in this Agreement; or

(c) the gross negligence or willful misconduct of Mirador or any Mirador Indemnified Party;

except, in each case ((a)–(c)), to the extent such claim results from or arises out of an event described in any one or multiple of clauses (a) through (c) of Section 7.1.2, in which case, as to such claim, each Party shall indemnify the other to the extent of their respective liability.

** **

7.1.2. Indemnification by Kira. Subject to Section 7.1.3, Kira will indemnify Mirador, its Affiliates and its and its Affiliates’ employees, officers and directors, Sublicensees and distributors (each, a “Mirador Indemnified Party”) from and against any Liability that the Mirador Indemnified Party may incur or otherwise be required to pay to one or more Third Parties in connection with any Third Party suit, investigation, claim or demand resulting from or arising out of:

(a) Kira’s or its Affiliates’ Exploitation of any Licensed Component or Licensed Product prior to the Effective Date;

39

(b) the breach by Kira of any of its representations, warranties or covenants set forth in this Agreement; or

(c) the gross negligence or willful misconduct of Kira or any Kira Indemnified Party;

except, in each case ((a)–(c)), to the extent such claim results from or arises out of an event described in any one or multiple of clauses (a) through (c) of Section 7.1.1, in which case, as to such claim, each Party shall indemnify the other to the extent of their respective liability.

** **

7.1.3. Indemnification of Penn.

(a) Mirador shall defend, indemnify and hold Penn and its respective trustees, officers, faculty, students, employees, contractors and agents (the “Penn Indemnitees”) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage to the extent arising out of Third Party claims or suits related to (i) this Agreement or any Sublicense, including (A) the development, testing, use, manufacture, promotion, sale or other disposition of any Licensed Product (including any product liability claim) that incorporates, uses or otherwise practices or is made, used or sold by or utilizing or practicing any inventions of the Penn Patents, (B) any enforcement action or suit brought by Mirador against a Third Party for infringement of Penn Patents, (C) any claim by a Third Party that the practice of Penn Patents or the design, composition, manufacture, use, sale or other disposition of any Licensed Product that incorporates any inventions of the Penn Patents infringes or violates any patent, copyright, trade secret, trademark or other intellectual property right of such Third Party, (D) any breach of this Agreement or Applicable Laws by Mirador or its Affiliates or Sublicensees and (ii) Mirador’s gross negligence, omissions or willful misconduct, provided that Mirador’s obligations pursuant to this Section 7.1.3 shall not apply to the extent such claims or suits result from the gross negligence or willful misconduct of any of Penn Indemnitees, as determined by a court of law.

(b) As a condition to a Penn Indemnitee’s right to receive indemnification under this Section 7.1.3, Penn shall: (i) promptly notify Mirador as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (ii) reasonably cooperate, and cause the individual Penn Indemnitees to reasonably cooperate, with Mirador in the defense, settlement or compromise of such claim or suit; and (iii) permit Mirador to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel. In no event, however, may Mirador compromise or settle any claim or suit in a manner which (A) admits fault or negligence on the part of Penn or any other Penn Indemnitee; (B) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action, without the prior written consent of Penn, or (C) grant any rights under the Penn Patents except for Sublicenses permitted under Article 2 of the Penn License. Penn shall reasonably cooperate with Mirador and its counsel in the course of the defense of any such suit, claim or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information and witnesses.

40

(c) Notwithstanding Section 7.1.3(b) above, in the event that Penn believes in good faith that a bona fide conflict exists between Mirador and Penn or any other Penn Indemnitee with respect to a claim or suit subject to indemnification hereunder, then Penn or any other Penn Indemnitee shall have the right to defend against any such claim or suit itself, including by selecting its own counsel, with any reasonable attorney’s fees and litigation expenses being paid for by Mirador. Mirador will pay such fees and expenses either directly or will reimburse Penn within thirty (30) days of Mirador’s receipt of invoices for such fees and expenses.

** **

7.1.4. Procedure. Each Party will notify the other Party in writing if it becomes aware of a claim for which such Party may seek indemnification hereunder. If any Proceeding is instituted against a Party (or another Kira Indemnified Party in the case of Kira or another Mirador Indemnified Party in the case of Mirador) with respect to which indemnity may be sought pursuant to Section 7.1.1 or 7.1.2 as applicable, such Party (the “Indemnified Party”) will give prompt written notice of the indemnity claim to the other Party (the “Indemnifying Party”) and provide the Indemnifying Party with a copy of any complaint, summons or other written notice that the Kira Indemnified Party or Mirador Indemnified Party, as applicable, receives in connection with any such claim. An Indemnified Party’s failure to deliver such written notice will relieve the Indemnifying Party of liability to the Kira Indemnified Party or Mirador Indemnified Party under Section 7.1.1 or 7.1.2 as applicable, only to the extent such delay is prejudicial to the Indemnifying Party’s ability to defend such claim. Provided that the Indemnifying Party is not contesting the indemnity obligation, the Kira Indemnified Party or Mirador Indemnified Party, as applicable, will permit the Indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated settlement or otherwise (subject to this Section 7.1) and any failure to contest such obligation prior to assuming control will be deemed to be an admission of the obligation to indemnify. The Indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim and will not settle or otherwise resolve such claim without the prior written consent of the Kira Indemnified Party or Mirador Indemnified Party, as applicable, which will not be unreasonably withheld, conditioned or delayed; *provided *that such consent will not be required with respect to any settlement involving only the payment of monetary awards for which the Indemnifying Party will be fully responsible. The Indemnified Party will cooperate with the Indemnifying Party in the Indemnifying Party’s defense of any claim for which indemnity is sought under this Agreement, at the Indemnifying Party’s cost and expense.

** **

7.2. Insurance.

** **

7.2.1. Mirador, at its sole cost and expense, must insure its activities in connection with the exercise of its rights under this Agreement and obtain, and keep in force and maintain Commercial Form General Liability Insurance (contractual liability included) with limits as follows:

Commercial Form Insurance

* *

  • (a) Each occurrence — $2,000,000;*

* *

  • (b) General aggregate — $2,000,000*

Prior to the commencement of Clinical Trials, if applicable, involving Licensed Product:

* *

  • (c) Clinical Trials liability insurance – $3,000,000*

Prior to the First Commercial Sale of a Licensed Product:

* *

  • (d) Products liability insurance – $3,000,000*
41

Kira and Mirador may periodically review the adequacy of the minimum amounts of insurance required by this Section 7.2.1, and shall mutually agree to adjust the limits should such a change be deemed prudent by the Parties.

** **

7.2.2. If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement.

** **

7.2.3. Mirador expressly understands, however, that the coverages and limits in Section 7.2.1 do not in any way limit Mirador’s liability or indemnification obligations. Mirador’s insurance will:

(a) be issued by an insurance carrier with an A.M. Best rating of “A” or better;

(b) provide for thirty (30) days’ advance written notice to Penn of any modification;

(c) state that Penn is endorsed as an additional insured with respect to the coverages in Section 7.2.1; and

(d) include a provision that the coverages will be primary and will not participate with nor will be excess over any valid and collectible insurance or program of self-insurance carried or maintained by Penn.

** **

7.2.4. Mirador must furnish to Penn and Kira (a) a valid certificate of insurance evidencing compliance with all requirements of this Agreement and (b) additional insured endorsements for Mirador’s applicable policies naming “The Trustees of the University of Pennsylvania” as an additional insured. Mirador must furnish both documents within thirty (30) days of the Effective Date, once per year thereafter and at any time there is a modification in such insurance.

** **

7.3. Limitation of Consequential Damages. Except for (a) claims of a Third Party that are subject to indemnification under this ARTICLE 7, (b) claims arising out of a Party’s Gross NEGLIGENCE OR willful misconduct or (c) a Party’s breach of Section 3.4 or ARTICLE 9, neither Party nor any of its Affiliates will be liable to the other Party or its Affiliates for any incidental, consequential, special, punitive or other indirect damages or lost or imputed profits or royalties, whether liability is asserted in contract, tort (including negligence and strict product liability), indemnity or contribution, and irrespective of whether that Party or any representative of that Party has been advised of, or otherwise might have anticipated the possibility of, any such loss or damage.

ARTICLE 8.

TERM; TERMINATION

** **

8.1. Term; Expiration. This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 8, will expire, in its entirety, upon the expiration of the last to expire Royalty Term under this Agreement with respect to all Licensed Products in all countries (such period, the “Term”):

** **


42

** **

8.2. Termination of this Agreement.

** **

8.2.1. Mirador’s Termination for Convenience. Mirador may terminate this Agreement (either in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis), for convenience by providing written notice of its intent to terminate to Kira, in which case, such termination will be effective ninety (90) days after Kira’s receipt of such written notice.

** **

8.2.2. Termination for Material Breach.

(a) Mirador’s Right to Terminate. If Mirador believes that Kira is in material breach of this Agreement, Mirador may deliver written notice of such material breach to Kira. If the breach is curable, Kira will have ninety (90) days following its receipt of such written notice to cure such breach. If Kira fails to cure such breach within such ninety (90) day period or the breach is not subject to cure (a “Kira Breach Event”), Mirador may terminate this Agreement by providing written notice to Kira, in which case, this Agreement will terminate on the date on which Kira receives such written notice; provided, however, that if (i) the relevant breach is curable, but not reasonably curable within ninety (90) days, and (ii) Kira is making a bona fide effort to cure such breach, Mirador’s right to terminate this Agreement on account of such breach will be suspended for so long as Kira is continuing to make such bona fide effort to cure such breach and if such breach is successfully cured, Mirador will no longer have the right to terminate this Agreement on account of such breach.

(b) Kira’s Right to Terminate. If Kira believes that Mirador is in material breach of this Agreement, Kira may deliver written notice of such material breach to Mirador. If the breach is curable, Mirador will have ninety (90) days following its receipt of such written notice to cure such breach (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within forty-five (45) days following its receipt of such written notice). If Mirador fails to cure such breach within the ninety (90) day or forty-five (45) day period, as applicable, or the breach is not subject to cure, Kira may terminate this Agreement by providing written notice to Mirador, in which case, this Agreement will terminate on the date on which Mirador receives such written notice; provided, however, that if (i) the relevant breach (A) does not involve Mirador’s failure to make a payment when due and (B) is curable, but not reasonably curable within ninety (90) days, and (ii) Mirador is making a bona fide effort to cure such breach, Kira’s right to terminate this Agreement on account of such breach will be suspended for so long as Mirador is continuing to make such bona fide effort to cure such breach and if such breach is successfully cured, Kira will no longer have the right to terminate this Agreement on account of such breach.

** **

8.2.3. Disputes Regarding Material Breach. Notwithstanding the foregoing, if the Breaching Party in Section 8.2.2 disputes in good faith the existence, materiality, or failure to cure of any breach, and provides written notice to the Non-Breaching Party of such dispute within the relevant cure period, the Non-Breaching Party will not have the right to terminate this Agreement in accordance with Section 8.2.2, unless and until the relevant dispute has been resolved in accordance with Section 10.14. During the pendency of such dispute, the relevant cure period shall be tolled, all the terms of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder.

** **

8.2.4. Termination for Insolvency. If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within sixty (60) days after the filing thereof (each, an “Insolvency Event”), the other Party may terminate this Agreement in its entirety by providing written notice of its intent to terminate this Agreement to the Party experiencing the Insolvency Event, in which case, this Agreement will terminate on the date on which the Party experiencing the Insolvency Event receives such written notice.

43

** **

8.2.5. Termination for Patent Challenge. Mirador and its Affiliates will not, directly or indirectly (including where such is done by a Third Party on behalf of Mirador or its Affiliates, at the urging of Mirador or its Affiliates or with the assistance of the Mirador or its Affiliates) challenge the validity, scope, or enforceability of or otherwise oppose any Licensed Patent, provided that if any Licensed Patent is asserted against Mirador or its Affiliate for activities authorized under this Agreement, then Mirador or its Affiliates is entitled to all and any defenses available to it including challenging the validity or enforceability of such Licensed Patent. If Mirador, its Affiliate or a Sublicensee participates directly or indirectly in a patent challenge, then, at Kira’s discretion:

(a) Kira may terminate this Agreement upon thirty (30) days’ prior written notice to Mirador (unless such patent challenge is dismissed within such thirty (30) day period), in which event such termination shall be deemed a termination by Kira pursuant to Section 8.2.2(b) with no further right of Mirador to cure; or

(b) The following shall apply:

(i) during the pendency of such patent challenge action or proceeding (including any appeals), the royalties and milestone payments payable hereunder will increase to double the applicable amounts;

(ii) if, following such patent challenge, at least one (1) claim of the Licensed Patents which is subject to the patent challenge survives the patent challenge by not being found invalid or unenforceable, regardless of whether such claim is amended as part of the patent challenge, the royalties and milestone payments shall increase to triple the applicable amounts, effective as of dismissal, judgment, settlement, withdrawal or other closure of such patent challenge;

(iii) Mirador, its Affiliates and the Sublicensee(s) will have no right to recoup any milestone payment or royalty (including any increased amount) paid before such action or proceeding or during the period in which such action or proceeding is pending (including on appeal), no matter the outcome of such action or proceeding; and

(iv) Mirador shall pay all reasonable costs and expenses incurred by Kira and Penn (including, but not limited to, Kira’s and Penn’s actual attorneys’ fees) in connection with such action or proceeding. Kira may bill Mirador as frequently as monthly concerning such costs and expenses, and Mirador shall make payment no later than thirty (30) days after receiving an invoice from Kira. Notwithstanding any other provision of the Agreement, as between the Parties with respect to any such patent challenge, Kira will have full control and authority to defend the Licensed Patents in the action or proceeding and will not be required to share any work product concerning such action or proceeding with Mirador, its Affiliates or the Sublicensee(s).

** **

8.3. Mirador’s Right of Setoff. Following a Kira Breach Event, if Mirador does not terminate this Agreement in its entirety in accordance with Section 8.2.2(a) on account of such Kira Breach Event, in addition to any other remedies Mirador may have under this Agreement or otherwise, Mirador may set off against any amounts owed to Kira pursuant to any provision of this Agreement one-hundred percent (100%) of all direct damages (excluding, in all cases, loss of profits) suffered by Mirador as a result of such Kira Breach Event (the “Setoff Amount”) until such time as all such damages have been recovered by Mirador. Notwithstanding the foregoing, if Kira notifies Mirador in writing that it disputes Mirador’s assertion that Kira is in material breach of this Agreement or the amount set off by Mirador, pending the Parties’ agreement or other resolution regarding the appropriate setoff (if any), Mirador will pay the Setoff Amount into an escrow account established for purposes of this Section 8.3; provided, however, that Mirador shall continue to pay to Kira in accordance with the terms of this Agreement all amounts necessary for Kira to fulfill its financial obligations to Penn.

44

** **

8.4. Consequences of Expiration or Termination of the Agreement.

** **

8.4.1. In General. If this Agreement expires or is terminated in whole or in part with respect to one or more countries or Licensed Products by a Party pursuant to this ARTICLE 8, the following terms will apply to this Agreement, either in its entirety or with respect to the Licensed Product in any country that is the subject of such termination or the Licensed Product that is the subject of such termination, as the case may be:

(a) each Party will take all action required under Section 9.3 if requested by the other Party;

(b) termination or expiration of this Agreement for any reason will be without prejudice to any rights or financial compensation that will have accrued to the benefit of a Party prior to such expiration or termination. Such expiration or termination will not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement; and

(c) the following provisions of this Agreement will survive the expiration or termination of this Agreement: ARTICLE 1, Section 3.1.2(a) (with respect to Mirador’s responsibility regarding Third Parties to which it has granted Sublicenses), Section 3.3, Section 4.4.9 (with respect to any royalty obligations accrued prior to expiration or termination), Sections 4.6 through 4.8 (inclusive, solely to the extent applicable and with respect to any amounts due or payment obligations accrued prior to expiration or termination), Section 5.1, Section 5.4 (with respect to proceedings to the extent relating to events occurring prior to the effective date of termination other than in the case of termination pursuant to Section 8.2.2(b), 8.2.4 or 8.2.5), Section 6.5, ARTICLE 7, this Section 8.4.1, Section 8.4.2, Sections 9.1 through 9.4 (inclusive, for the time period set forth in Section 9.1), Section 9.5, and ARTICLE 10.

** **

8.4.2. Early Termination. If this Agreement is terminated in its entirety or in part by a Party pursuant to Sections 8.2.1, 8.2.2, 8.2.3, 8.2.4 or 8.2.5 the following terms will apply with respect to any Licensed Product or any Licensed Product in any country that is the subject of such termination (i.e., all Licensed Products worldwide in the case of termination of this Agreement in its entirety, the applicable Licensed Product in the Territory in the case of termination of this Agreement for a particular Licensed Product, or the applicable Licensed Products in the terminated countries in the case of termination of this Agreement for a particular country, as the case may be):

(a) except as set forth in Section 8.4.2(f), the applicable licenses granted by Kira to Mirador with respect to such Licensed Product in the relevant country or countries or in the Territory, as applicable, under this Agreement will terminate;

(b) except as set forth in this Section 8.4.2, Mirador will have no further rights and Kira will have no further obligations with respect to such Licensed Products in the relevant country or countries or such Licensed Products in the Territory, as applicable;

45

(c) solely in the case of termination of this Agreement in its entirety, neither Mirador, nor its acquiror, will be required to make an Accelerated Milestone Payment pursuant to Section 10.4.2 to the extent that notice of such termination is provided by Mirador or its acquiror prior to the due date of such Accelerated Milestone Payment;

(d) if terminated with respect to a particular country or countries, the Territory will be automatically amended to exclude the relevant country or countries;

(e) if terminated with respect to a particular Licensed Product or Licensed Products, the definition of Licensed Product will be automatically amended to exclude the relevant Licensed Product or Licensed Products;

(f) any permitted Sublicense of Mirador will, at the Sublicensee’s option, survive such termination on the condition that the relevant Sublicensee is not in material breach of any of its obligations under such Sublicense. In order to effect this provision, at the request of the Sublicensee, Kira will enter into a direct license with the Sublicensee on terms that are substantially the same terms as the applicable terms of this Agreement. Notwithstanding the foregoing, Kira will not be required to undertake obligations in addition to those required by this Agreement, and Kira’s rights and obligations under the assumed Sublicense or such direct license will be consistent with its rights and obligations under this Agreement, taking into account the scope of the license granted under such direct license;

(g) except with respect to any termination by Mirador under Section 8.2.2(a) and subject to Section 8.4.2(i), Mirador will, as promptly as practicable, (i) transfer to Kira possession and ownership of all Regulatory Approvals solely relating to the Exploitation of any Licensed Component or Licensed Product in the relevant country or countries, and (ii) grant to Kira a “Right of Reference” (including rights of reference or cross-reference as discussed in FDA’s regulations (see 21 C.F.R. §§ 312.23(b), 314.3(b), 601.51(a)) and any foreign counterparts to such regulations) with respect to any Regulatory Approvals that relate to the Exploitation of any Licensed Component or Licensed Product;

(h) except with respect to any termination by Mirador under Section 8.2.2(a), effective upon such termination, Mirador hereby grants to Kira a non-exclusive, royalty-bearing, irrevocable, perpetual, license, which Kira may sublicense through multiple tiers, under all Mirador Agreement Technology Controlled by Mirador or its Affiliates to Exploit Licensed Components and Licensed Products in the Field in the relevant country or countries; provided, that if the grant of such license to Kira with respect to any Know-How or Patent included in the Mirador Agreement Technology or Kira’s exercise of such license would trigger a royalty or other payment to a Third Party or would require compliance with any provision of any license between Mirador and a Third Party, Mirador will so notify Kira in writing and such Know-How or Patent will only be included in the foregoing license if, following receipt of such notice, Kira agrees in writing to reimburse Mirador for all such payments payable to such Third Party after the effective date of such grant and to comply with any such provision; and provided, further, that such license will not grant Kira any rights with respect to any active ingredient in a Licensed Product that is not a Licensed Component;

(i) to the extent Kira receives a license from Mirador pursuant to Section 8.4.2(h) Kira will pay Mirador or its designated Affiliate a royalty of [***] percent ([***]%) of the worldwide Net Sales of such Licensed Product (including Net Sales by Kira’s Affiliates and licensees). The terms of Sections 1.100, 4.4.2, 4.6, 4.7 and 4.8 will apply with respect to Kira’s payment of such royalty, mutatis mutandis; and

(j) any other requests by Kira relating to the reversion of the Licensed Components and Licensed Products in the Field in the relevant country or countries, including with respect to any ongoing clinical trials and the transfer of materials or intellectual property, will be negotiated by the Parties in good faith at the time of such termination.

46

ARTICLE 9.

CONFIDENTIALITY

** **

9.1. Confidentiality. During the Term and for five (5) years thereafter, each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will: (a) keep the Disclosing Party’s Confidential Information confidential; (b) not publish, or allow to be published, and will not otherwise disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose, except, in each case, to the extent expressly permitted under this Agreement (including, for clarity, to exercise any of its rights and perform any of its obligations) or otherwise agreed in writing. Without limiting the generality of the foregoing, to the extent that either Party provides the other Party any Confidential Information owned by any Third Party, the Receiving Party will handle such Confidential Information in accordance with the terms of this ARTICLE 9 applicable to a Receiving Party.

** **

9.2. Authorized Disclosure. Notwithstanding Section 9.1, each Party may disclose the other Party’s Confidential Information to the extent such disclosure is reasonably necessary to:

(a) following discussion between the Parties of such disclosure, file or prosecute patent applications as contemplated by this Agreement;

(b) subject to the remainder of this Section 9.2, prosecute or defend litigation;

(c) exercise its rights and perform its obligations hereunder; *provided *that such disclosure is covered by terms of confidentiality similar to those set forth herein (except with respect to the duration of such terms which will be commercially reasonable under the circumstances);

(d) subject to the remainder of this Section 9.2, its advisors (including financial advisors, attorneys and accountants), actual or potential acquisition partners, financing sources, investors, underwriters or sub(licensees) on a need to know basis; *provided *that such disclosure is covered by terms of confidentiality similar to those set forth herein (except with respect to the duration of such terms which will be commercially reasonable under the circumstances) which may include professional ethical obligations;

(e) subject to the remainder of this Section 9.2 and Section 9.4, comply with Applicable Law; or

(f) subject to Section 9.4, include such Confidential Information in Regulatory Filings.

In addition to the foregoing, Mirador may disclose Kira’s Confidential Information to Third Parties in connection with the actual or potential Exploitation of Licensed Components or Licensed Products; provided that such disclosure is covered by terms of confidentiality similar to those set forth herein.

If a Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to Sections 9.2(b) or 9.2(e), the disclosing Party will, to the extent possible, give reasonable advance notice of such disclosure to the other Party and take reasonable measures to ensure confidential treatment of such information.

47

** **

9.3. Expiration or Termination of this Agreement. Following the expiration or termination of this Agreement, if requested by the Disclosing Party, the Receiving Party will return or destroy, at the Receiving Party’s election, all data, files, records and other materials containing or comprising the Disclosing Party’s Confidential Information, except to the extent such Confidential Information is necessary or useful to conduct surviving obligations or exercise surviving rights. Notwithstanding the foregoing, (a) the Receiving Party will be permitted to retain one copy of such data, files, records, and other materials for archival and legal compliance purposes and (b) the Receiving Party will not be required to delete or destroy any electronic back-up tapes or other electronic back-up files that have been created solely by the Receiving Party’s or its Affiliate’s automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with its or their standard archiving and back-up procedures.

** **

9.4. Applicable Law; SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement or activities performed hereunder to the extent required to comply with Applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory; provided, that, to the extent such disclosure includes terms or information that have not previously been so disclosed, such Party will provide the other Party a reasonable opportunity to review such disclosure and reasonably consider the other Party’s comments regarding confidential treatment sought for such disclosure.

** **

9.5. Use of Name. Mirador, its Affiliates and Sublicensees may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative, without the prior written consent of Penn. Notwithstanding the foregoing, Mirador may use the name of Penn in a non-misleading and factual manner solely in (a) executive summaries, business plans, offering memoranda and other similar documents used by Mirador for the purpose of raising financing for the operations of Mirador as related to Licensed Product, or entering into commercial contracts with Third Parties, but in such case only to the extent necessary to inform a reader that the Penn Patents have been licensed by Mirador from Penn, and to inform a reader of the identity and published credentials of inventors of the intellectual property, and (b) any securities reports required to be filed with the Securities and Exchange Commission.

** **

9.6. Public Announcements; Publications.

** **

9.6.1. Announcements. Following the Effective Date, each Party may issue a press release regarding the signing of this Agreement in form(s) mutually agreed upon by the Parties. Except (a) as set forth in the preceding sentence and (b) as set forth in Section 9.4, neither Party may make any public announcement regarding this Agreement or activities hereunder without the prior written approval of Mirador. Notwithstanding the foregoing, subject to Section 9.6.2, Mirador may make scientific publications or public announcements concerning the Development, Manufacture or Commercialization activities with respect to any Licensed Component or Licensed Product under this Agreement without Kira’s prior written approval.

** **


48

** **

9.6.2. Publications. During the Term, Mirador will submit to Kira for review any proposed academic, scientific and medical publication or academic, scientific and medical public presentation that (i) contains Kira’s Confidential Information and is related to any Licensed Component or Licensed Product or to any activities conducted pursuant to this Agreement. Kira will review such publication or presentation for purposes of determining whether any portion of the proposed publication or presentation contains Kira’s Confidential Information. Mirador will submit written copies of such proposed publication or presentation to Kira no later than thirty (30) days before submission for publication or presentation (or five (5) Business Days in advance in the case of an abstract). Kira will provide its comments with respect to such publications and presentations within five (5) Business Days after its receipt of such written copy. If requested by Kira, Mirador will redact Kira’s Confidential Information from any such proposed publication or presentation. Mirador will consider all other comments provided by Kira regarding such proposed publication or presentation in good faith. Mirador will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication. During the Term, Kira will not publish, present or make any publication with respect to the Licensed Components, Licensed Products or Licensed Technology specifically related to the Licensed Components or Licensed Products.

ARTICLE 10.

MISCELLANEOUS

** **

10.1. Assignment. This Agreement will not be assignable by either Party to any Third Party without the written consent of the non-assigning Party. Notwithstanding the foregoing, either Party may assign this Agreement or its rights and obligations under this Agreement, without the written consent of the other Party, to an Affiliate or to a Third Party that acquires all or substantially all of the business or assets of such Party to which this Agreement relates (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms of this Agreement, provided that such Affiliate or Third Party maintains the rights and abilities to perform the obligations of the assigning Party under this Agreement. This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 10.1 will be void.

** **

10.2. No Discrimination. Neither Kira nor Mirador will discriminate against any employee or applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap or veteran status.

** **

10.3. Change of Control of Kira.

** **

10.3.1. Notification. Kira (or its successor) will notify Mirador in writing promptly (and in any event within seven (7) Business Days) following the execution of a definitive agreement by Kira (or its successor), its Affiliates or its equity holders that results in a Change of Control of Kira (or its successor).

** **

10.3.2. Effects of Change of Control of Kira. If, during the period beginning six (6) months after the Effective Date and continuing for the duration of the Term, Kira (or its successor) undergoes a Change of Control, then upon the effective date of such Change of Control and solely to the extent that Kira no longer has any upstream obligation to Penn under the Penn License with respect to Development reporting and diligence obligations, Mirador’s obligation to provide Kira (or its successor) with Development reports in accordance with Section 2.1.2 and to use Commercially Reasonable Efforts in accordance with Section 2.5 will terminate. Notwithstanding the foregoing, this Section 10.3.2 shall not apply with a Change of Control that occurs, directly or indirectly, in conjunction with Kira going public through a reverse merger transaction or an initial public offering.

** **


49

** **

10.4. Change of Control of Mirador.

** **

10.4.1. Notification. Mirador (or its successor) will notify Kira in writing promptly (and in any event within seven (7) Business Days) following the execution of a definitive agreement by Mirador, its Affiliates or its equity holders that results in a Change of Control of Mirador.

** **

10.4.2. Effects of Change of Control. If, during the Term, Mirador undergoes a Change of Control, then Mirador (or its successor) will pay to Kira an amount equal to [***] percent ([***]%) of the immediately subsequent unachieved Development milestone payment (as of the date of such Change of Control) for a Licensed Antibody Product set forth in Section 4.3.1 (the “Accelerated Milestone Payment”), which such Accelerated Milestone Payment will be due and payable by Mirador (or its successor) within one-hundred twenty (120) days after the closing of such Change of Control of Mirador; *provided *that, (a) if Mirador (or its successor) provides Kira with a notice of termination of this Agreement within such one-hundred twenty (120) day period, then neither Mirador nor its successor will be required to make any Accelerated Milestone Payment to Kira in connection with such Change of Control; and (b) (i) if the milestone event for the Accelerated Milestone Payment is the next-achieved milestone event (whether by actual achievement, or as a result of becoming payable pursuant to being a skipped milestone under Section 4.3.4), then the amount due and payable for such subsequent achievement will be [***] percent ([***]%) of the applicable amount set forth in Section 4.3.1, or (ii) if the milestone event for the Accelerated Milestone Payment is not the next subsequently achieved milestone event (e.g., if further Development of the applicable Licensed Product is paused in favor of pursuing a new Indication), then Mirador (or its successor) will have the right to offset the amount of such Accelerated Milestone Payment against any future milestone event achieved following a Change of Control. For clarity, for purposes of this Section 10.4.2, only milestone payments for the Commencement of a Clinical Trial for the 1st Indication of a Licensed Antibody Product or the Regulatory Approval in the U.S. for the 1st Indication of a Licensed Antibody Product can be deemed “immediately subsequent.”

** **

10.5. Force Majeure. Each Party will be excused from the performance of its obligations (other than payment obligations) under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides written notice of the Force Majeure to the other Party. Such excusal will continue for so long as the condition constituting a Force Majeure continues, on the condition that the nonperforming Party continues to use Commercially Reasonable Efforts to resume performance of its obligations under this Agreement.

** **

10.6. Representation by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, no presumption will exist or be implied against the Party that drafted such terms and provisions.

** **

10.7. Notices. All written notices which are required or permitted hereunder will be in writing and sufficient if delivered personally or sent by nationally-recognized overnight courier, or through email to the applicable email address, addressed as follows:

If to Mirador:

Mirador Therapeutics, Inc.

4902 Headquarters Point, Suite 300

San Diego, CA 92121

Attention: Chief Legal Officer, Timothy K. Andrews

Email: [***]

50

with a copy to:

Ropes & Gray, LLP

Prudential Tower

800 Boylston Street

Boston, MA 02199-3600

Attention: Abigail Gregor

Email: Abigail.Gregor@ropesgray.com

If to Kira:

Kira Pharmaceuticals

245 Main Street, 12th FL

Cambridge, MA 02142

Attention: Matthew E. Ros, COO

Email: [***]

or to such other address as the Party to whom written notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such written notice will be deemed to have been given and received by the other Party: (a) when delivered if personally delivered; or (b) on receipt if sent by overnight courier or email.

** **

10.8. Amendment. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each of Mirador and Kira.

** **

10.9. Waiver. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either Party of any breach of any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself.

** **

10.10. Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause or portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law.

** **

10.11. Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement.

** **

10.12. Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States of America or other countries that may be imposed upon or related to Kira or Mirador from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate Governmental Authority.

51

** **

10.13. Governing Law. This Agreement, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of The State of New York, without regard to conflict of law principles thereof.

** **

10.14. Dispute Resolution. Subject to Section 10.14.3 regarding the resolution of certain Patent and Know-How-related disputes, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a “Dispute”), it will be resolved pursuant to Sections 10.14.1 and 10.14.2.

** **

10.14.1. Escalation to Executive Officers. Either Party may refer any Dispute to the Executive Officers of the Parties, who will confer in good faith on the resolution of the issue, by delivering written notice to the other Party. If the Executive Officers are unable to agree on the resolution of any such Dispute within thirty (30) days (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then within thirty (30) days after the end of such thirty (30)-day period or such other mutually-agreed period of time, either Party may, by written notice to the other Party, elect to initiate an arbitration proceeding pursuant to the procedures set forth in Section 10.14.2 for purposes of having the matter settled (the “Arbitration Notice”).

** **

10.14.2. Arbitration. A Party may elect to resolve any Dispute pursuant to arbitration only after the Parties have escalated the Dispute to the Executive Officers pursuant to Section 10.14.1, which process shall be a condition precedent to arbitration. The Parties will follow the following procedures to resolve such Dispute under arbitration:

(a) Binding Arbitration. Within thirty (30) days following a Party’s receipt of the Arbitration Notice, the Parties will submit such Dispute to, and such Dispute will be finally resolved by, binding arbitration in accordance with the International Arbitration Rules & Procedures of the International Centre for Dispute Resolution (“ICDR”), the international division of the American Arbitration Association (“AAA”). The arbitral tribunal shall be composed of three impartial arbitrators bound by The Code of Ethics for Arbitrators in Commercial Disputes, all of whom will have relevant experience in the pharmaceutical industry (and the field of pharmaceutical development, commercialization or any other relevant area, as applicable), one appointed by each of the Parties within fifteen (15) days after the Arbitration Notice, and the third who will chair the arbitral tribunal appointed by the Party-appointed arbitrators within fifteen (15) days after the appointment of the second arbitrator, or, failing agreement by the Party-appointed arbitrators, by the ICDR in accordance with the list method of Article 13.6 in the International Arbitration Rules. If, at the time of the arbitration, the Parties agree in writing to submit the Dispute to a single arbitrator, said single arbitrator will (i) have relevant experience in the pharmaceutical industry (and the field of pharmaceutical development, commercialization or any other relevant area, as applicable) and (ii) be appointed by agreement of the Parties within thirty (30) days after the Arbitration Notice, or, failing such agreement, by the ICDR in accordance with the list method of Article 13.6 in the International Arbitration Rules. In no case shall any arbitrator have participated in a prior mediation involving either Party unless explicitly agreed to by the Parties. Unless otherwise agreed by the Parties, the seat and place of the arbitration proceedings shall be New York, NY, U.S.A. and the language of the arbitration shall be English. The Dispute will not be subject to the ICDR International Expedited Procedures, regardless of the amount in controversy, unless otherwise agreed by the Parties in writing.

(b) Limited Discovery. Documentary discovery may be conducted at the discretion of the arbitrator(s), provided that any such discovery will (i) be limited to documents directly relating to the Dispute, (ii) be conducted pursuant to document discovery procedures as set forth under the laws of the International Bar Association Rules of Evidence, and (iii) be conducted subject to the schedule stipulated by the Parties, or in the absence of stipulation, the schedule ordered by the arbitrator(s). At the request of a Party, the arbitrator(s) may at their discretion order the deposition of witnesses. Depositions shall be limited to a maximum of three (3) depositions per Party, each of a maximum of four (4) hours duration, unless the arbitrator(s) otherwise determine. Notwithstanding any provision of this Section 10.14.2 to the contrary, all discovery must be completed within ninety (90) days after the appointment of the arbitrator(s).

52

(c) Awards and Fees. The arbitrator(s) have the authority to make awards of declaratory relief and monetary damages, but they may not award damages excluded under Section 7.3, and will not under any circumstances have the authority or power to grant (i) equitable relief or (ii) orders for specific performance. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrator(s), or, in the absence of such determination, each Party will pay its own expenses, including attorney’s fees.

(d) Rulings. All arbitration proceedings must be completed within one hundred eighty (180) days after the Arbitration Notice. The Parties hereby agree that, subject to the provisions of this Section 10.14.2, the arbitrator(s) has authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrator(s) deem reasonable and necessary with or without petition therefor by the Parties as well as the final award. The final award will be issued no more than thirty (30) days after the final submissions of the Parties, or as soon thereafter as practicable. All rulings by the arbitrator(s) will be final and binding on the Parties. The arbitrator(s) shall issue a reasoned decision that accompanies the final award.

(e) Enforcement of Rulings by Courts of Competent Jurisdiction. Any ruling issued by the arbitrator(s) pursuant to Section 10.14.2(d) may be enforced, to the extent that such ruling complies with the provisions of Section 10.14.2(c), in any court having jurisdiction over any of the Parties or any of their respective assets.

(f) Confidentiality. All activities undertaken by the arbitrator(s) or the Parties pursuant to this Section 10.14.2 will be conducted subject to obligations of confidentiality no less restrictive than those set forth in ARTICLE 9. Further, the Parties acknowledge and agree that their respective conduct during the course of the arbitration, their respective statements and all information exchanged in connection with the arbitration, and the conduct of the arbitration and any information produced thereunder is Confidential Information under this Agreement and subject to the provisions of ARTICLE 9.

** **

10.14.3. Patent and Know-How Disputes. Notwithstanding the foregoing in this Section 10.14, if a dispute arises between the Parties under this Agreement with respect to the interpretation, scope, validity, enforceability, applicability or term of any Patent or inventorship or ownership of any Know-How, then such dispute shall not be resolved pursuant to Sections 10.14.1 and 10.14.2, but instead may be brought by either Party in the federal courts of New York, in each case, (a) unless the Parties agree in writing to submit such claim to arbitration pursuant to Sections 10.14.1 and 10.14.2 or (b) except to the extent federal jurisdiction cannot be maintained, in which case such claim will be submitted to arbitration pursuant to Sections 10.14.1 and 10.14.2.

** **

10.14.4. Equitable Relief. Notwithstanding the foregoing in this Section 10.14, nothing contained in this Agreement will in any way limit or preclude a Party from, at any time, seeking or obtaining equitable relief hereunder, whether preliminary or permanent, including a temporary or permanent restraining order, preliminary or permanent injunction, specific performance or any other form of equitable relief, from any United States court of competent jurisdiction if necessary to protect the interests of such Party. Each Party agrees that its unauthorized release of the other Party’s Confidential Information or its breach of Section 3.4 of this Agreement will cause irreparable damage to other Party for which recovery of damages would be inadequate, and that such other Party will be entitled to seek timely injunctive relief with respect to such breach, without the need to show irreparable harm or the inadequacy of monetary damages as a remedy, and without the requirement of having to post bond or other security, as well as any further relief that may be granted by a court of competent jurisdiction.

** **


53

** **

10.15. Entire Agreement. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof, including the CDA, which is hereby superseded and replaced in its entirety as of the Effective Date.

** **

10.16. Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing contained herein will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.

** **

10.17. Transparency Laws. Kira agrees that Mirador may publicly disclose any information related to (a) this Agreement, (b) any payment or transfer of value made to Kira by Mirador hereunder, or (c) any payment or transfer of value made by Kira to any Third Party or Affiliate in connection with this Agreement, in each case (a)-(c), to the extent reasonably required by transparency industry regulations and transparency laws and by any means, including reporting through any government platform or system, Mirador’s and its Affiliates’ websites or any other platform or system. Kira will promptly (and in any event within ten (10) Business Days) provide Mirador with any such information as reasonably requested by Mirador to enable compliance with transparency industry regulations and transparency laws.

** **

10.18. Interpretation. Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include,” “includes” and “including” will be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein,” “hereof” and “hereunder,” and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Schedules or Exhibits will be construed to refer to Sections, Schedules or Exhibits of this Agreement, and references to this Agreement include all Schedules and Exhibits hereto, (h) provisions that require that a Party or the Parties hereunder “agree,” “consent,” “approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes, e-mail or otherwise (but excluding text messaging or instant messaging), (i) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (j) any action or occurrence deemed to be effective as of a particular date will be deemed to be effective as of 11:59 PM ET on such date and (k) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or.”

** **

10.19. No Third Party Rights or Obligations. Penn is hereby deemed a third party beneficiary under this Agreement. Except for Penn and each Indemnified Party pursuant to ARTICLE 7, no provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligations in any Person not a Party to this Agreement.

** **

10.20. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

** **

10.21. Counterparts. This Agreement may be executed in two counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by digital transmission (e.g., .pdf), each of which will be binding when received by the applicable Party. The Parties may execute this Agreement by electronically transmitted signature and such electronically transmitted signature will be as effective as an original executed signature page.

** **

10.22. Kira Suzhou. Kira Suzhou hereby acknowledges and agrees that: (a) this Agreement constitutes a valid sublicense under the Intercompany License Agreement; and (b) Kira Suzhou will not (i) terminate the Intercompany License Agreement, (ii) amend the Intercompany License Agreement in a manner that would adversely affect Mirador’s rights hereunder or (iii) take any other action with respect to the Intercompany License Agreement that would adversely affect Mirador’s rights hereunder, in each case (i)-(iii), without first obtaining Mirador’s written consent, which consent may be withheld in Mirador’s sole discretion.

* *

[Signature Page Follows]

54

** **

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their representatives thereunto duly authorized as of the Effective Date.

MIRADOR THERAPEUTICS, INC.
By: /s/ Mark C. McKenna
Name: Mark C. McKenna
Title: Chairman and Chief Executive Officer
KIRA PHARMACEUTICALS
By: /s/ Patrick Crutcher
Name: Patrick Crutcher
Title: Director
Acknowledged and agreed SOLELY with respect to Section 10.22:
KIRA PHARMACEUTICALS (SUZHOU) LTD.
By: /s/ Nguyen Van Hy
Name: Nguyen Van Hy
Title: Legal Representative
55

** **

Schedule 1.81

** **

Licensed Antibody

[***]

** **

Schedule 1.84

** **

Licensed Compound

[***]

** **

** **

Schedule 1.87

** **

Licensed Patents

[***]

Schedule 1.109

** **

Penn Patents

[***]** **

Schedule 1.114

** **

Physical Materials

** **

[***]

** **

Schedule 3.1.2

** **

Sublicense Development Report

[***]

** **

** **

Schedule 3.1.4

** **

Mouse Models

[***]

** **

** **

Schedule 3.2.3

** **

Third Party Vendor and Contract Agreements

[***]

** **

** **

Schedule 4.5

** **

Kira In-License Agreements

[***]

Schedule 6.2

** **

Disclosure Schedule

[***]

Back to all agreements